<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12473851</article-id><article-id pub-id-type="pmcid-ver">PMC12473851.1</article-id><article-id pub-id-type="pmcaid">12473851</article-id><article-id pub-id-type="pmcaiid">12473851</article-id><article-id pub-id-type="pmid">41012551</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17091216</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-01216</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Nanoformulation-Based Transdermal Drug Delivery: A Paradigm Shift in Antiparasitic Therapy for Zoonotic Diseases</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="Y">Yuan</given-names></name><xref rid="af1-pharmaceutics-17-01216" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-01216" ref-type="aff">2</xref><xref rid="fn1-pharmaceutics-17-01216" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiu</surname><given-names initials="R">Ruoxuan</given-names></name><xref rid="af1-pharmaceutics-17-01216" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-01216" ref-type="aff">2</xref><xref rid="fn1-pharmaceutics-17-01216" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="C">Chengxiang</given-names></name><xref rid="af1-pharmaceutics-17-01216" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-01216" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="J">Junqi</given-names></name><xref rid="af1-pharmaceutics-17-01216" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-01216" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="D">Dawei</given-names></name><xref rid="af1-pharmaceutics-17-01216" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-01216" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5170-1670</contrib-id><name name-style="western"><surname>Luo</surname><given-names initials="W">Wanhe</given-names></name><xref rid="af3-pharmaceutics-17-01216" ref-type="aff">3</xref><xref rid="af4-pharmaceutics-17-01216" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="S">Shanxiang</given-names></name><xref rid="af1-pharmaceutics-17-01216" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-01216" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ge</surname><given-names initials="Z">Zhiyi</given-names></name><xref rid="af3-pharmaceutics-17-01216" ref-type="aff">3</xref><xref rid="af4-pharmaceutics-17-01216" ref-type="aff">4</xref><xref rid="c1-pharmaceutics-17-01216" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="X">Xiuge</given-names></name><xref rid="af1-pharmaceutics-17-01216" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-01216" ref-type="aff">2</xref><xref rid="c1-pharmaceutics-17-01216" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Muzzalupo</surname><given-names initials="R">Rita</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Zannella</surname><given-names initials="C">Carla</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>De Filippis</surname><given-names initials="A">Anna</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-01216"><label>1</label>Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, 1 Weigang, Nanjing 210095, China; <email>2023807142@stu.njau.edu.cn</email> (Y.Z.); <email>2024807139@stu.njau.edu.cn</email> (R.X.); <email>cxw55@stu.njau.edu.cn</email> (C.W.); <email>2021207003@stu.njau.edu.cn</email> (J.W.); <email>gdawei0123@njau.edu.cn</email> (D.G.); <email>jiangsx66@njau.edu.cn</email> (S.J.)</aff><aff id="af2-pharmaceutics-17-01216"><label>2</label>Center for Veterinary Drug Research and Evaluation, Laboratory of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Nanjing Agricultural University, 1 Weigang, Nanjing 210095, China</aff><aff id="af3-pharmaceutics-17-01216"><label>3</label>College of Animal Science and Technology, Tarim University, Alar 843300, China; <email>luowanhe0728@163.com</email></aff><aff id="af4-pharmaceutics-17-01216"><label>4</label>Engineering Laboratory of Tarim Animal Diseases Diagnosis and Control, Xinjiang Production &amp; Construction Corps, Alaer 843300, China</aff><author-notes><corresp id="c1-pharmaceutics-17-01216"><label>*</label>Correspondence: <email>gzy20220620@163.com</email> (Z.G.); <email>vetgao@njau.edu.cn</email> (X.G.)</corresp><fn id="fn1-pharmaceutics-17-01216"><label>&#8224;</label><p>These authors contribute equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>17</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">497664</issue-id><elocation-id>1216</elocation-id><history><date date-type="received"><day>24</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>14</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>27</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-17-01216.pdf"/><abstract><p>Nanoparticle-based transdermal drug delivery systems (TDDS) have emerged as a revolutionary approach for antiparasitic therapy, addressing key challenges such as poor bioavailability, systemic toxicity, and drug resistance. This review highlights the advancements in nanotechnology-driven TDDS for combating zoonotic parasitic diseases, including leishmaniasis, malaria, and infections treated by broad-spectrum drugs like ivermectin and albendazole. By leveraging nanocarriers such as liposomes, nanoemulsions, and microneedles, which enhance skin permeation, enable controlled drug release, and improve targeting specificity. For instance, deformable transfersomes and ethosomes achieve high transdermal efficiency without chemical adjuvants, while microneedle arrays physically bypass the stratum corneum for precise delivery. Furthermore, sustained-release hydrogels and stimuli-responsive nanoparticles optimize therapeutic efficacy and reduce adverse effects. Despite promising results, clinical translation faces challenges in manufacturing scalability, long-term safety, and accessibility in resource-limited settings. Future directions include bioinspired nanocarriers, artificial intelligence (AI)-driven design, and integration with global health initiatives like &#8220;One Health&#8221;, all aimed at ensuring equitable implementation. This review highlights the transformative potential of nanotechnology in achieving sustainable antiparasitic solutions for zoonotic diseases.</p></abstract><kwd-group><kwd>nanoparticles</kwd><kwd>transdermal drug delivery</kwd><kwd>antiparasitic drug</kwd><kwd>leishmaniasis</kwd><kwd>malaria</kwd><kwd>one health</kwd><kwd>zoonotic diseases</kwd></kwd-group><funding-group><award-group><funding-source>Engineering Laboratory for Tarim Animal Diseases Diagnosis and Control of Xinjiang Production and Construction Production &amp; Construction Corps</funding-source><award-id>ELDC202403</award-id></award-group><award-group><funding-source>Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)</funding-source></award-group><funding-statement>This study was funded by the opening project of the Engineering Laboratory for Tarim Animal Diseases Diagnosis and Control of Xinjiang Production and Construction Production &amp; Construction Corps (ELDC202403) and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-01216"><title>1. Introduction</title><p>According to the World Health Organization&#8217;s 2024 report on Neglected Tropical Diseases (NTDs), parasitic infections remain a devastating global health burden, affecting over a billion people worldwide and causing significant morbidity, mortality, and socioeconomic disruption, particularly in resource-limited regions [<xref rid="B1-pharmaceutics-17-01216" ref-type="bibr">1</xref>]. Among these, zoonotic parasitic diseases&#8212;transmitted between animals and humans&#8212;pose a critical and escalating threat. The report emphasizes that factors such as climate change, population migration, and uncertain funding outlooks may lead to the spread of many NTDs beyond their traditional endemic areas in low-income countries and tropical regions [<xref rid="B1-pharmaceutics-17-01216" ref-type="bibr">1</xref>]. The Coronavirus Disease 2019 (COVID-19) pandemic has fundamentally reshaped global public health awareness, and the &#8220;One Health&#8221; concept has become a key framework for addressing complex infectious diseases due to its core value in coordinating human&#8211;animal-environment health synergy [<xref rid="B2-pharmaceutics-17-01216" ref-type="bibr">2</xref>]. As demonstrated in a global assessment of schistosomiasis control, environmental strategies that target the intermediate snail host&#8212;such as molluscicide application or biological control&#8212;reduced disease prevalence by 92 &#177; 5%. This result significantly outperformed drug-only interventions, which achieved a reduction of only 37 &#177; 7%. Such evidence highlights the practical impact of the &#8216;One Health&#8217; framework. Interrupting transmission through ecological management improves control of zoonotic parasitic diseases while reducing dependence on chemical therapies. Consequently, this approach lowers the risk of drug resistance and supports more sustainable disease management [<xref rid="B3-pharmaceutics-17-01216" ref-type="bibr">3</xref>]. Notably, shifts in vector distribution due to climate change, coupled with health services not yet fully recovering from disruptions caused by the COVID-19 pandemic, are reshaping disease transmission patterns [<xref rid="B1-pharmaceutics-17-01216" ref-type="bibr">1</xref>]. The report indicates that NTDs cause billions of dollars in losses annually in low- and middle-income countries, while the limitations of traditional treatment options continue to drive this figure upward [<xref rid="B1-pharmaceutics-17-01216" ref-type="bibr">1</xref>] (<xref rid="pharmaceutics-17-01216-f001" ref-type="fig">Figure 1</xref>). Therefore, it is imperative to develop innovative and sustainable solutions to prevent and treat zoonotic parasitic diseases.</p><p>Among the various strategies to combat parasitic diseases, transdermal drug delivery systems have received a lot of attention due to their unique advantages [<xref rid="B4-pharmaceutics-17-01216" ref-type="bibr">4</xref>]. Compared with oral or injectable drug delivery, transdermal drug delivery exhibits several advantages, such as avoiding the first-pass effect of the liver, no gastrointestinal irritation, good compliance, ability to reduce animal stress, convenient use, and high safety [<xref rid="B5-pharmaceutics-17-01216" ref-type="bibr">5</xref>]. How to make the drug transdermal absorption through the stratum corneum is the focus of the transdermal drug delivery system. Enhancing the permeability of transdermal drugs can be achieved by both physical and chemical methods. Common physical methods include iontophoresis, electroporation, ultrasound introduction, pressure wave, laser cautery, and thermal promotion of permeation, while chemical methods are generally used to enhance transdermal penetration of drugs through chemical permeation promoters [<xref rid="B6-pharmaceutics-17-01216" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-17-01216" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-17-01216" ref-type="bibr">8</xref>]. However, the traditional physical and chemical methods to promote transdermal delivery tend to enhance the rate of transdermal penetration by increasing drug solubility, diffusion coefficient, and reservoir effect, which often leads to the overuse of chemical enhancers and the production of toxic side effects, and thus unmask more drawbacks [<xref rid="B9-pharmaceutics-17-01216" ref-type="bibr">9</xref>]. Confronted with these difficulties in transdermal drug delivery, nanotechnology may represent a good choice.</p><p>Nanotechnology is often defined as the ability to produce and process materials at the nanoscale or to manipulate nano-objects. The nanoscale is often specified as 1 to 100 nm in the field of physics because the electromagnetic and quantum characteristics of nano-objects are more prominent in this scale [<xref rid="B10-pharmaceutics-17-01216" ref-type="bibr">10</xref>]. Based on the special properties of nano-objects, nanotechnology has been used in various fields of science, and one important application area is nanodrug carriers. Nanodrug carriers include liposomes, transfersomes, ethosomes, and nanoemulsions in which drugs can be encapsulated by dissolution, dispersion, encapsulation, adsorption, and coupling [<xref rid="B11-pharmaceutics-17-01216" ref-type="bibr">11</xref>]. In the context of transdermal drug delivery, nanodrug carriers offer innovative solutions to overcome the skin&#8217;s natural barrier, the stratum corneum, which is a major obstacle to preventing drug penetration. The ex vivo and in vivo behaviors of drugs are determined by the physicochemical properties of the nano carriers, which can be used to enhance drug efficacy, reduce side effects, enhance therapeutic index, and improve drug compliance.</p><p>This review focuses on the application of nanotechnology in transdermal treatment systems for parasitic diseases, summarizing its mechanisms of action and the important role it plays in malaria, leishmaniasis, and broad-spectrum antiparasitic drugs. By placing this discussion within the framework of the &#8220;One Health&#8221; approach, we aim to provide insights that can inform future health policy directions and contribute to the development of innovative and sustainable strategies for combating zoonotic parasitic diseases.</p></sec><sec id="sec2-pharmaceutics-17-01216"><title>2. Advantages of Nano Transdermal Delivery System</title><sec id="sec2dot1-pharmaceutics-17-01216"><title>2.1. Transdermal Mechanism of Nanoformulations</title><p>As the primary physical barrier protecting the human body against external stimuli, the brick-and-mortar structure of the stratum corneum in the outermost epidermal layer severely restricts the transdermal permeation efficiency of conventional drugs through the highly ordered arrangement of intercellular lipids. Nanocarriers break this barrier through a multidimensional synergistic mechanism, significantly enhancing the delivery efficacy of anti-parasitic drugs. The specific mechanisms are as follows and summarized in <xref rid="pharmaceutics-17-01216-f002" ref-type="fig">Figure 2</xref>.</p><p>The transdermal mechanisms of liposomes involve synergistic effects through multiple pathways: First, the phospholipids in liposomes exhibit high compatibility with stratum corneum lipids, leading to structural disintegration of liposomes and subsequent release of phospholipids. These released phospholipids infiltrate the stratum corneum and reorganize into lamellar structures, thereby widening lipid intercellular channels and enhancing drug permeation [<xref rid="B12-pharmaceutics-17-01216" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-17-01216" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-17-01216" ref-type="bibr">14</xref>]. Second, their hydration effect increases stratum corneum water content, alters the arrangement of intercellular lipid layers in corneocytes, and reduces barrier density. Additionally, intact liposomes can directly penetrate through corneocytes or utilize skin appendage pathways such as hair follicles or sweat glands for delivery [<xref rid="B15-pharmaceutics-17-01216" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-01216" ref-type="bibr">16</xref>]. Surfactant-driven deformable carriers create transient permeation channels by disrupting stratum corneum lipid organization. Transfersomes are formed by modifying liposomal composition. Surfactants embedded in the vesicle membrane enable extreme deformability, allowing penetration through pores several times smaller than their own size [<xref rid="B17-pharmaceutics-17-01216" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-01216" ref-type="bibr">18</xref>]. Ethosomes are multilamellar vesicles incorporating high-concentration ethanol into conventional liposomal formulations. The high ethanol concentration enhances the mobility of polar lipid heads in membrane components, thereby increasing lipid fluidity and membrane flexibility. It also reduces the density of intercellular lipid domains, facilitating vesicle deformation during permeation. Consequently, higher ethanol content correlates with greater permeation flux. Drug release and absorption in deeper skin layers result from liposome-skin lipid fusion, which persists throughout the transdermal process [<xref rid="B9-pharmaceutics-17-01216" ref-type="bibr">9</xref>,<xref rid="B19-pharmaceutics-17-01216" ref-type="bibr">19</xref>]. For instance, trifluralin-loaded transfersomes demonstrate the potential of deformable nanocarriers for targeted cutaneous leishmaniasis treatment, achieving high-efficiency transdermal delivery without permeation enhancers [<xref rid="B20-pharmaceutics-17-01216" ref-type="bibr">20</xref>]. Co-loaded nitazoxanide-quercetin nanotransfersomal exhibit a 4-fold enhancement in skin permeation compared to conventional transfersomes [<xref rid="B21-pharmaceutics-17-01216" ref-type="bibr">21</xref>]. In addition, an ethosomal patch, an innovative antimalarial transdermal nanosystem, has been developed for increasing the cumulative permeation of artesunate by 1.57-fold compared to conventional patches after 8 h of administration [<xref rid="B22-pharmaceutics-17-01216" ref-type="bibr">22</xref>].</p><p>Nanoemulsions significantly enhance transdermal drug permeation through a triple synergistic mechanism. First, surfactant components disrupt the lipid arrangement in the stratum corneum while expanding intercellular spaces through hydration, creating permeation pathways for drug molecules [<xref rid="B23-pharmaceutics-17-01216" ref-type="bibr">23</xref>]. Second, the nanoemulsion structure enables effective solubilization of drugs, especially lipophilic drugs, thereby increasing the drug concentration gradient across the skin and enhancing permeation [<xref rid="B24-pharmaceutics-17-01216" ref-type="bibr">24</xref>]. Finally, the nanoscale particle size combined with superior wettability improves skin contact and permeation efficiency [<xref rid="B9-pharmaceutics-17-01216" ref-type="bibr">9</xref>]. This layer-by-layer mechanism establishes nanoemulsions as ideal transdermal carriers. For example, nanoemulsions effectively deliver chalcone to deep skin layers (dermis), the parasitic site of Leishmania pathogens [<xref rid="B25-pharmaceutics-17-01216" ref-type="bibr">25</xref>]. Studies have demonstrated enhanced skin permeation using nanoemulsions loaded with C6I/TC1/TC2, which are promising antileishmanial drugs for treating Leishmania infections [<xref rid="B26-pharmaceutics-17-01216" ref-type="bibr">26</xref>].</p><p>Microneedle arrays (MNs), composed of needle-like structures with diameters of several micrometers, penetrate the skin surface to create microchannels, providing an innovative solution for transdermal drug delivery. MNs overcome the limitations of traditional methods through precise targeting capability, offering higher safety, efficacy, and painless administration [<xref rid="B27-pharmaceutics-17-01216" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-01216" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-01216" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-01216" ref-type="bibr">30</xref>]. For instance, a novel dissolving microneedle patch has been successfully designed to enhance the skin permeability of amphotericin B. The microneedles penetrated rat skin to a depth of 303 &#177; 8 &#181;m, dissolved rapidly, and formed micropores that caused no significant cellular damage, with natural healing within 30 min [<xref rid="B31-pharmaceutics-17-01216" ref-type="bibr">31</xref>]. Similarly, a hydrogel-forming microneedle combined with a polyethylene glycol (PEG) reservoir has been developed for cystic Echinococcosis treatment, and in vitro permeation tests showed an albendazole permeation amount of 4584.43 &#177; 26.61 &#181;g/cm<sup>2</sup> [<xref rid="B32-pharmaceutics-17-01216" ref-type="bibr">32</xref>]. Liposomes [<xref rid="B14-pharmaceutics-17-01216" ref-type="bibr">14</xref>] (including transfersomes [<xref rid="B18-pharmaceutics-17-01216" ref-type="bibr">18</xref>] and ethosomes [<xref rid="B9-pharmaceutics-17-01216" ref-type="bibr">9</xref>]), nanoemulsions [<xref rid="B23-pharmaceutics-17-01216" ref-type="bibr">23</xref>], and microneedle arrays [<xref rid="B27-pharmaceutics-17-01216" ref-type="bibr">27</xref>] overcome the inherent barrier limitations of the stratum corneum through their distinctive multidimensional synergistic mechanisms&#8212;such as the structural compatibility and deformability adaptation of liposomes, the triple synergistic enhancement of permeability in nanoemulsions, and the physical microchannel creation by microneedle arrays. This breakthrough significantly augments the transdermal delivery efficiency of antiparasitic drugs, serving as a critical foundation for subsequent controlled release and targeted delivery systems.</p><p>In summary, although liposomes, transfersomes, ethosomes, nanoemulsions, and microneedle arrays all aim to overcome the stratum corneum barrier, their mechanisms and optimal applications differ significantly. Liposomes rely on biocompatibility and fusion with skin lipids, making them suitable for delivering a wide range of drugs, but their penetration efficiency is inherently limited. Transfersomes and ethosomes, as optimized versions, achieve enhancer-free transdermal delivery through superior deformability (imparted by surfactants or high-concentration ethanol, respectively), making them particularly effective for hydrophobic drugs. Nanoemulsions leverage the synergistic effects of surfactant-induced disruption and solubilization, offering greater potential for scalable manufacturing. In contrast, microneedles provide a paradigm-shifting physical strategy that completely bypasses the stratum corneum, enabling the most precise control over drug release and the highest delivery efficiency, albeit with challenges related to production cost and mechanical integrity. Consequently, the selection of an appropriate nanocarrier must be guided by a holistic consideration of drug properties, target disease, production costs, and the intended clinical application.</p></sec><sec id="sec2dot2-pharmaceutics-17-01216"><title>2.2. Controlled Release and Targeted Delivery of Nanoformulations</title><p>The success of antiparasitic therapy relies not only on efficient drug penetration through the skin barrier but also on achieving long-acting and low-toxicity therapeutic outcomes through precise controlled-release [<xref rid="B33-pharmaceutics-17-01216" ref-type="bibr">33</xref>] and targeting strategies [<xref rid="B34-pharmaceutics-17-01216" ref-type="bibr">34</xref>]. Nanoparticle-based drug delivery systems employ multidimensional collaborative mechanisms to prolong therapeutic duration temporally [<xref rid="B35-pharmaceutics-17-01216" ref-type="bibr">35</xref>] and enhance lesion targeting efficiency spatially [<xref rid="B36-pharmaceutics-17-01216" ref-type="bibr">36</xref>], providing comprehensive solutions spanning from localized permeation to dynamic regulation for parasitic infections. This section systematically elaborates the core mechanisms of sustained-release depot construction and targeting synergy, elucidating their pivotal roles in reducing recurrence risk and minimizing host damage.</p><p>The sustained-release mechanisms of transdermal nanoformulations achieve high-efficiency antiparasitic therapy through multi-mechanism synergy. Controlled-release carriers such as liposomes [<xref rid="B37-pharmaceutics-17-01216" ref-type="bibr">37</xref>] and nanoemulsions [<xref rid="B34-pharmaceutics-17-01216" ref-type="bibr">34</xref>] regulate drug release via matrix diffusion or degradation-controlled processes, forming long-acting drug depots in the skin to reduce dosing frequency. The synergistic interaction between reservoir effects and gradient-driven permeation further optimizes drug delivery: depot-accumulated high-concentration gradients drive drug penetration into subcutaneous tissues, preventing systemic plasma concentration spikes [<xref rid="B36-pharmaceutics-17-01216" ref-type="bibr">36</xref>]. Building on this, multistage release strategies&#8212;employing biphasic rapid-sustained release designs or combination drug loading&#8212;enable insecticidal-immunomodulatory synergy, lowering recurrence risks [<xref rid="B38-pharmaceutics-17-01216" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceutics-17-01216" ref-type="bibr">39</xref>]. This hierarchical sustained-release system, transitioning from local retention to dynamic permeation and from monotherapy to combinatorial regulation, provides precise long-acting solutions for parasitic infections. Based on this mechanism, a topical ivermectin formulation has been successfully developed, where solid lipid nanoparticles (SLNs) confer superior sustained-release efficacy for treating scabies [<xref rid="B40-pharmaceutics-17-01216" ref-type="bibr">40</xref>]. Moreover, a novel electrospun wound dressing has been designed and evaluated with excellent antileishmanial activity, achieving sustained drug release for up to two weeks [<xref rid="B41-pharmaceutics-17-01216" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-17-01216" ref-type="bibr">42</xref>].</p><p>Additionally, hydrogels have emerged as ideal topical drug delivery vehicles. Hydrogels have garnered significant attention due to their unique properties, including low cost, excellent biocompatibility, non-toxicity, stimuli-responsive behavior, and tunable drug release kinetics [<xref rid="B43-pharmaceutics-17-01216" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-17-01216" ref-type="bibr">44</xref>]. Nanostructured lipid carrier (NLC)-based hydrogels represent a transformative approach for localized antileishmanial therapy. Inspired by the relevance theory, glucantime-loaded NLC hydrogels have been generated with controlled drug release performance [<xref rid="B45-pharmaceutics-17-01216" ref-type="bibr">45</xref>].</p><p>The passive targeting effect of transdermal nanoformulations primarily optimizes skin penetration efficiency through the physical properties of carriers (e.g., particle size, deformability). For example, trifluralin-loaded transfersomes, with a nanoscale particle size of 140.3 &#177; 2.3 nm and a high deformation index (DI = 43.5 &#177; 1.0), can permeate through microscopic pores in the stratum corneum [<xref rid="B20-pharmaceutics-17-01216" ref-type="bibr">20</xref>]. Additionally, the negatively charged surface of TFS may enhance interactions with macrophage phagosomal membranes, promoting intracellular drug delivery [<xref rid="B20-pharmaceutics-17-01216" ref-type="bibr">20</xref>]. Experimental validation revealed that rhodamine-labeled TFS exhibited a 4.13-fold increase in endocytosis efficiency compared to free solutions, directly attributed to the adaptive membrane penetration of their elastic vesicular structures. This property demonstrates significant advantages in antileishmanial therapy: trifluralin-loaded transfersomes achieved 90.87% inhibition of intracellular amastigotes in macrophages at 50 &#181;g/mL, showing a 1.68-fold efficacy enhancement over conventional TFL solutions that exhibited 54% inhibition [<xref rid="B20-pharmaceutics-17-01216" ref-type="bibr">20</xref>]. In a similar strategy, rifampicin-loaded nanotransfersomes also rely on nanoscale size and elasticity for passive targeting, further validating the universality of this mechanism in transdermal antiparasitic therapy [<xref rid="B46-pharmaceutics-17-01216" ref-type="bibr">46</xref>]. Furthermore, elastic liposomes are demonstrated to enhance immune responses via transdermal delivery of the Plasmodium falciparum surface antigen (PfMSP-1<sub>19</sub>), effectively activating Langerhans cells and promoting their migration to draining lymph nodes [<xref rid="B47-pharmaceutics-17-01216" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-17-01216" ref-type="bibr">48</xref>].</p><p>The deep integration of these mechanisms and advantages marks the transition of nanocarrier-based transdermal delivery systems into a new era of precision and long-acting performance in antiparasitic therapy. Currently, this technology has displayed significant clinical value in zoonotic parasitic diseases such as leishmaniasis and malaria. Its specific applications and future challenges will be systematically discussed below.</p></sec></sec><sec id="sec3-pharmaceutics-17-01216"><title>3. Application of Nanoformulations in the Treatment of Parasitic Diseases</title><p>Nanotechnology-based systems, leveraging their unique technological advantages, provide highly promising solutions for antiparasitic drug delivery. The application of nanocarriers significantly enhances drug targeting specificity, effectively protects drugs or immunotherapeutic agents from extracellular degradation, and optimizes biopharmaceutical and pharmacological properties, thereby improving therapeutic efficacy while reducing side effects [<xref rid="B49-pharmaceutics-17-01216" ref-type="bibr">49</xref>]. Currently, nanocarrier-based therapy has been extensively used in the control of parasitic diseases, among which Leishmaniasis and Malaria are the most noteworthy aspects. Herein, we take Leishmaniasis and Malaria as examples to discuss the application of nanoformulations for parasitic disease control.</p><sec id="sec3dot1-pharmaceutics-17-01216"><title>3.1. Leishmaniasis</title><p>Leishmaniasis, caused by protozoan parasites of the genus Leishmania (family Trypanosomatidae), is transmitted through the bite of infected sand flies, resulting in a spectrum of clinical manifestations including visceral (VL), cutaneous (CL), mucosal (ML), and mucocutaneous leishmaniasis (MCL) [<xref rid="B50-pharmaceutics-17-01216" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceutics-17-01216" ref-type="bibr">51</xref>]. The severity of illness is determined by the virulence of specific Leishmania species and the host immune response, ranging from self-resolving cutaneous lesions to life-threatening visceral organ failure [<xref rid="B51-pharmaceutics-17-01216" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceutics-17-01216" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-17-01216" ref-type="bibr">53</xref>]. Macrophages, serving as the primary host cells for Leishmania parasites, play a pivotal role in pathogenesis. Despite substantial research efforts, challenges such as drug resistance and limited therapeutic accessibility persist, necessitating accelerated development of novel therapies to address this ongoing global health burden [<xref rid="B54-pharmaceutics-17-01216" ref-type="bibr">54</xref>].</p><p>Current pharmacotherapy for Leishmaniasis faces multifaceted limitations, including drug toxicity, pathogen resistance, and restricted access to treatment resources, particularly in low-income regions. First-line pentavalent antimonials have been progressively phased out due to widespread resistance [<xref rid="B55-pharmaceutics-17-01216" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceutics-17-01216" ref-type="bibr">56</xref>]. Alternative agents such as miltefosine, paromomycin, and pentamidine are further constrained by emerging resistance, prohibitive costs, and severe adverse effects. In light of these challenges, nanotechnology-driven formulations have emerged as a promising strategy to improve drug efficacy and reduce toxicity for both visceral [<xref rid="B57-pharmaceutics-17-01216" ref-type="bibr">57</xref>] and cutaneous leishmaniasis [<xref rid="B58-pharmaceutics-17-01216" ref-type="bibr">58</xref>]. Particularly noteworthy is that nanoformulations can enhance the therapeutic efficacy of existing pharmacophores, such as quinoline compounds, by improving their delivery and targeting capabilities [<xref rid="B59-pharmaceutics-17-01216" ref-type="bibr">59</xref>]. Herein, we systematically examine recent advances in therapeutic strategies against Leishmaniasis, focusing on transdermal penetration enhancement, safety optimization, wound healing promotion, and immune modulation, while addressing translational challenges and future research trajectories.</p><p>Transdermal delivery technologies have undergone multistage iterative optimization. Early research focused on nanoemulsions: a chalcone nanoemulsion has been developed using a mixed system of anionic and nonionic surfactants, which enhanced dermal permeation of trans-chalcone and 3&#8242;-(trifluoromethyl)-chalcone by 1.26-fold and 2.41-fold, respectively [<xref rid="B25-pharmaceutics-17-01216" ref-type="bibr">25</xref>,<xref rid="B60-pharmaceutics-17-01216" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-17-01216" ref-type="bibr">61</xref>]. The fluorinated derivative achieved 88.31 &#956;g/g skin retention (vs. 45.86 &#956;g/g for the free form) due to fluorine-enhanced hydrophobicity [<xref rid="B25-pharmaceutics-17-01216" ref-type="bibr">25</xref>]. Garcia et al. further validated this potential: an ethanol-oleic acid/Tween<sup>&#174;</sup>-80 nanoemulsion with particle size modulation of 147&#8211;273 nm enabled sustained release of anti-leishmanial compounds (first-order kinetics and Weibull model), demonstrating 2-fold increased parasiticidal activity and reduced macrophage cytotoxicity [<xref rid="B26-pharmaceutics-17-01216" ref-type="bibr">26</xref>]. Recent advances highlight deformable nanocarriers for enhancer-free transdermal delivery. Second-generation systems achieve precision delivery through structural engineering. A prime example is trifluralin-loaded transfersomes, which have a particle size of 140 nm and an ultralow polydispersity index (PDI, 0.006). This achieved 86% encapsulation efficiency and 24 h sustained release without permeation enhancers [<xref rid="B20-pharmaceutics-17-01216" ref-type="bibr">20</xref>]. This reduced Leishmania IC<sub>50</sub> values by 2.86 to 3.07-fold, suppressed amastigotes by 90.87% (vs. 54% for free drug), and demonstrated efficient macrophage internalization and biocompatibility [<xref rid="B20-pharmaceutics-17-01216" ref-type="bibr">20</xref>]. Furthermore, it is reported that nitazoxanide-quercetin nanotransfersomal gel (NTZ-QUR-NTG) enhanced skin permeation 4-fold, increased macrophage uptake 10-fold, elevated concentration of cytotoxicity 50% (CC<sub>50</sub>) from 49.77 &#956;g/mL to 71.95 &#956;g/mL, and significantly reduced lesion size in mice with minimized systemic toxicity [<xref rid="B21-pharmaceutics-17-01216" ref-type="bibr">21</xref>]. Interestingly, microneedle technology physically bypasses the stratum corneum barrier. Based on this mechanism, a PVP-carboxymethylcellulose microneedle patch has been successfully developed with 303 &#177; 8 &#956;m penetration depth, releasing amphotericin B within 30 min through self-sealing micropores, achieving 86% anti-leishmanial activity [<xref rid="B31-pharmaceutics-17-01216" ref-type="bibr">31</xref>]. Additionally, engineered electrospun core&#8211;shell nanofibers have been demonstrated to sustainably release 84% glucantime over 9 h, maintaining therapeutic drug concentrations for prolonged efficacy [<xref rid="B62-pharmaceutics-17-01216" ref-type="bibr">62</xref>].</p><p>To enhance the safety profile and immunomodulatory efficacy of nanoformulations, breakthroughs have been achieved across multiple dimensions. In nanomaterial innovation, silymarin-selenium nanoparticles exhibit a skin deposition rate of 82.21%, which reduced local toxicity by inhibiting trypanothione reductase activity and improving cytocompatibility [<xref rid="B63-pharmaceutics-17-01216" ref-type="bibr">63</xref>] (<xref rid="pharmaceutics-17-01216-f003" ref-type="fig">Figure 3</xref>). The Rabia team has engineered rifampicin-loaded nanotransfersomes combined with a chitosan-based gel, achieving 3-fold enhanced skin permeability and reduced IC<sub>50</sub> values through passive macrophage targeting, thereby minimizing systemic exposure while boosting therapeutic efficacy via apoptosis induction [<xref rid="B46-pharmaceutics-17-01216" ref-type="bibr">46</xref>]. In novel delivery system design, a glucantime-loaded nanostructured lipid carrier (NLC) hydrogel has been formulated that enabled sustained drug release, enhanced skin retention in murine models, and, compared to injectable formulations, this system significantly reduced lesion size, parasite burden, and systemic toxicity, offering a non-invasive therapeutic strategy [<xref rid="B45-pharmaceutics-17-01216" ref-type="bibr">45</xref>]. For immune modulation, Lanza et al. pioneered a LiHyp1 recombinant antigen-based vaccine delivered via dissolving microneedles (DMNs) and cationic liposomes (CL). This approach elicited high-titer antibody responses in mice, suppressed L. donovani infection, and established a novel paradigm for anti-leishmanial immunotherapy [<xref rid="B64-pharmaceutics-17-01216" ref-type="bibr">64</xref>].</p><p>Functionalized nanomaterials synergize intelligent drug release with multimodal mechanisms to promote chronic ulcer repair. On the basis of this mechanism, engineered chitosan-polyethylene oxide nanofibers loaded with berberine have been successfully designed, achieving gradient release over 14 days (80% released within the first 3 days). This system demonstrated potent larvae growth inhibition (IC<sub>50</sub> = 0.24 &#181;g/mL) and excellent biocompatibility [<xref rid="B41-pharmaceutics-17-01216" ref-type="bibr">41</xref>]. Furthermore, its efficacy has been validated in accelerating Leishmania ulcer healing, noting stable berberine release kinetics coupled with dual antibacterial activity against Staphylococcus aureus and Escherichia coli and sensor compatibility for real-time wound microenvironment monitoring [<xref rid="B42-pharmaceutics-17-01216" ref-type="bibr">42</xref>]. Similarly, a PVP-PVA-clay hydrogel has been shown to achieve 15 h sustained release of N-methyl glucamine under 1.5% clay conditions, reducing lesions by 99% in L. amazonensis-infected models [<xref rid="B65-pharmaceutics-17-01216" ref-type="bibr">65</xref>]. A cobalt-60 radiation-crosslinked PVP-PEG-agar hydrogel loaded with amphotericin B exhibited 12 h continuous drug release with thermal/radiation stability, achieving 100% parasitic growth inhibition within 48 h while integrating sterilization and long-term anti-infection functions [<xref rid="B66-pharmaceutics-17-01216" ref-type="bibr">66</xref>].</p><p>Nanoparticle-based transdermal delivery technologies, through strategies such as deformable nanocarriers, microneedle patches, and smart hydrogels, have significantly enhanced transdermal efficiency and targeting specificity in the treatment of Leishmaniasis, while reducing systemic toxicity via sustained-release designs. However, their clinical translation remains constrained by manufacturing complexity, insufficient long-term biosafety validation, and accessibility challenges in resource-limited regions. Future efforts should prioritize the development of intelligent responsive systems (e.g., enzyme/pH dual-sensitive hydrogels), artificial intelligence (AI)-driven carrier optimization, and multimechanistic combination therapies. Concurrently, leveraging global health governance frameworks such as the &#8220;One Health&#8221; initiative will be critical to advancing technological equity and accelerating the elimination of cutaneous leishmaniasis.</p></sec><sec id="sec3dot2-pharmaceutics-17-01216"><title>3.2. Malaria</title><p>Malaria is a major infectious disease that causes severe morbidity, mortality, and economic burden globally [<xref rid="B67-pharmaceutics-17-01216" ref-type="bibr">67</xref>]. Although significant efforts have been made to eradicate Malaria, the number of malaria cases worldwide still reached 249 million in 2022, resulting in 608,000 deaths [<xref rid="B68-pharmaceutics-17-01216" ref-type="bibr">68</xref>]. The burden of Malaria remains particularly severe in countries such as Nigeria, Uganda, the Democratic Republic of the Congo, and Mozambique [<xref rid="B68-pharmaceutics-17-01216" ref-type="bibr">68</xref>]. Malaria is caused by a single-celled parasite known as Plasmodium, which is transmitted to humans through the bites of female Anopheles mosquitoes, continuously threatening the lives of millions of people worldwide. There are five known species of Plasmodium that can cause human malaria, including Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium ovale, and Plasmodium knowlesi, with Plasmodium falciparum having the highest mortality rate [<xref rid="B69-pharmaceutics-17-01216" ref-type="bibr">69</xref>].</p><p>The treatment of malaria mainly depends on chemical drugs such as chloroquine, lumefantrine, primaquine, artemisinin, and its derivatives. While these drugs have achieved certain effectiveness in controlling malaria, their effectiveness is increasingly influenced by various factors, including the emergence of multidrug resistance, nonspecific targeting of intracellular parasites, low solubility and bioavailability of the drugs, and significant toxicity of the medications [<xref rid="B70-pharmaceutics-17-01216" ref-type="bibr">70</xref>,<xref rid="B71-pharmaceutics-17-01216" ref-type="bibr">71</xref>]. Increasing resistance manifests itself in the ability of the parasite to survive and multiply at a certain concentration of the drug that would normally be killed, so it is important to seek drug combinations and new strategies. The WHO recommends the use of artemisinin-based combination therapies (ACTs) for the treatment of malaria, including artesunate-amodiaquine, artemether-lumefantrine, artesunate-sulfadoxine-pyrimethamine, dihydroartemisinin-piperaquine, and artesunate-mefloquine [<xref rid="B72-pharmaceutics-17-01216" ref-type="bibr">72</xref>]. However, they also face issues such as high costs, differences in drug metabolism characteristics, potential toxicity, and insufficient availability [<xref rid="B72-pharmaceutics-17-01216" ref-type="bibr">72</xref>]. Furthermore, problems such as high transmission rates of Plasmodium parasites, resistance of mosquito vectors to insecticides, logistical challenges in implementing control measures, and population mobility pose greater difficulties for malaria control efforts. To overcome these difficulties, in recent years, innovations in nanoparticle-based drug delivery technology have provided breakthrough solutions [<xref rid="B68-pharmaceutics-17-01216" ref-type="bibr">68</xref>]. Next, we systematically review relevant advances, focusing on three key dimensions: enhancement of targeting specificity, reversal of drug resistance, and mitigation of toxicity, aiming to provide scientific evidence for optimizing antimalarial strategies.</p><p>Improving drug targeting specificity represents a core breakthrough direction in nanotechnology. Ethosomes containing artesunate and febrifugine into a patch matrix to form a composite transdermal patch have been prepared, achieving 8 h cumulative permeation 1.57 times higher than conventional patches, with 100% parasite clearance and zero recurrence, demonstrating the high efficiency of transdermal delivery [<xref rid="B22-pharmaceutics-17-01216" ref-type="bibr">22</xref>]. The transdermal nanogel platform exemplifies this progress, as its tunable size, adhesive properties, and sustained-release capabilities can effectively enhance drug retention in the skin layers and improve local targeting, offering a novel strategy for antimalarial therapy [<xref rid="B73-pharmaceutics-17-01216" ref-type="bibr">73</xref>]. The Zech team further optimized an artemisinin-based microemulsion spray [<xref rid="B74-pharmaceutics-17-01216" ref-type="bibr">74</xref>]. In a cerebral malaria model, this formulation achieved a blood concentration exceeding 500 ng/mL, doubled the efficacy compared to artesunate microemulsions, and enabled complete pathogen eradication [<xref rid="B74-pharmaceutics-17-01216" ref-type="bibr">74</xref>]. Similarly, artemisone-loaded solid lipid nanoparticles, through precise regulation of particle size and crystallinity, elevated drug concentration at the stratum corneum-epidermis junction to 62.632 &#956;g/mL (versus 12.792 &#956;g/mL for artemisone-loaded niosomes), demonstrating the significant efficacy of nanoparticles in optimizing dermal drug delivery concentration [<xref rid="B75-pharmaceutics-17-01216" ref-type="bibr">75</xref>] (<xref rid="pharmaceutics-17-01216-f003" ref-type="fig">Figure 3</xref>). In the field of immunomodulation, an elastic liposomal vaccine delivering Plasmodium falciparum antigen PfMSP-119 has been developed, which markedly enhanced humoral and cell-mediated immune responses [<xref rid="B48-pharmaceutics-17-01216" ref-type="bibr">48</xref>], maintained peak IgG-specific antibody titers for 70 days post-immunization, exhibited more sustained immune responses compared to conventional liposomes and intramuscular injection groups, and significantly increased IFN-&#947; secretion levels (approximately 9-fold higher than controls) [<xref rid="B47-pharmaceutics-17-01216" ref-type="bibr">47</xref>]. This immuno-based system provides a novel strategy for developing needle-free malaria vaccines [<xref rid="B47-pharmaceutics-17-01216" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-17-01216" ref-type="bibr">48</xref>].</p><p>To combat drug resistance, scientists have significantly enhanced therapeutic efficacy through co-delivery systems and novel mechanism designs. Aderibigbe&#8217;s team has developed an Arabic hydrogel dual-drug loading system co-encapsulating 4-aminoquinoline and curcumin that, by leveraging differential release kinetics (short-term anomalous transport and long-term quasi-Fickian diffusion), achieved synergistic effects, providing a new strategy for antiparasitic combination therapies [<xref rid="B38-pharmaceutics-17-01216" ref-type="bibr">38</xref>]. Further studies revealed that carbomer-polyacrylamide-soy protein composite hydrogels, through temporal regulation of chloroquine and curcumin diphosphate release via a super case II transport mechanism, enabled phased drug release to overcome current antimalarial drug resistance challenges [<xref rid="B39-pharmaceutics-17-01216" ref-type="bibr">39</xref>]. To address the limitations of resistance to conventional drugs, a hydroxypropyl methylcellulose-polyvinylpyrrolidone hydrogel nanoparticle loaded with curcumin has been successfully designed and prepared. This nanoparticle significantly enhanced curcumin&#8217;s antimalarial activity (exhibiting doubled potency compared to free drug at 25 mg/kg), prolonged drug circulation time, and improved bioavailability for enhanced efficacy [<xref rid="B76-pharmaceutics-17-01216" ref-type="bibr">76</xref>]. Moreover, Mavondo&#8217;s team has developed a pectin hydrogel-based percutaneous patch that not only suppresses parasitemia but also ameliorates inflammatory responses and anemia symptoms in malaria-infected Sprague-Dawley rats, offering a multifunctional solution for drug-resistant malaria treatment [<xref rid="B77-pharmaceutics-17-01216" ref-type="bibr">77</xref>].</p><p>In addressing systemic toxicity reduction, nanotechnology strategies focusing on localized controlled release and biocompatibility optimization have demonstrated remarkable efficacy. Nnamani et al. developed an artemether-loaded nanostructured lipid carrier hydrogel, which forms a localized drug reservoir through transdermal penetration, achieved a 26% cumulative permeation rate over 48 h, significantly enhanced drug stability, release controllability, and demonstrated no observable systemic exposure [<xref rid="B78-pharmaceutics-17-01216" ref-type="bibr">78</xref>]. Notably, the transdermal route itself possesses an inherent capacity to circumvent common gastrointestinal side effects and first-pass metabolism associated with oral antimalarials, enabling a source reduction in systemic toxicity risks, a feature particularly pronounced in novel transdermal formulations like nanogel and film [<xref rid="B72-pharmaceutics-17-01216" ref-type="bibr">72</xref>]. Conventional oral administration of primaquine (PMQ) may induce adverse effects and undergo significant first-pass metabolism in the liver, thereby compromising therapeutic efficacy. Ananda&#8217;s team pioneered the exploration of PMQ transdermal patch technology combined with solid microneedles (Dermaroller<sup>&#174;</sup>) [<xref rid="B79-pharmaceutics-17-01216" ref-type="bibr">79</xref>]. Their comprehensive evaluation included multiple parameters such as thickness, weight uniformity, and pH values. In vitro and ex vivo tests on PMQ release and permeation through rat skin confirmed the system&#8217;s safety profile, with all formulations demonstrating optimal performance, establishing a safe paradigm for long-term medication [<xref rid="B79-pharmaceutics-17-01216" ref-type="bibr">79</xref>].</p><p>Looking forward, although nanoparticle-based drug delivery technologies have demonstrated advantages in targeting specificity and safety profiles, their large-scale application still requires overcoming cost constraints and manufacturing barriers to provide sustainable technological support for global malaria eradication. Beyond the prominent examples of leishmaniasis and malaria, the versatility of nanotransdermal delivery systems holds significant promise for addressing a broader spectrum of zoonotic parasitic infections. This potential is further amplified by the convergence of nanotechnologies across different administration routes, a pivotal development exemplified by the success of nanoformulations for diseases like Chagas disease via oral or parenteral routes [<xref rid="B80-pharmaceutics-17-01216" ref-type="bibr">80</xref>]. Together with the advances in transdermal delivery detailed here, this collectively represents an overarching &#8216;paradigm shift&#8217; towards nano-enabled therapies. In the specific context of transdermal delivery, helminthic infections such as cystic echinococcosis [<xref rid="B81-pharmaceutics-17-01216" ref-type="bibr">81</xref>] and lymphatic filariasis [<xref rid="B82-pharmaceutics-17-01216" ref-type="bibr">82</xref>] face challenges similar to those discussed, including poor drug bioavailability, systemic toxicity, and the need for prolonged therapy. As highlighted in section four, nanotechnological approaches, particularly microneedle-integrated systems, demonstrate remarkable efficacy in enhancing transdermal delivery, achieving targeted deposition (e.g., lymphatic targeting), and enabling sustained release, thereby improving therapeutic outcomes while mitigating adverse effects [<xref rid="B29-pharmaceutics-17-01216" ref-type="bibr">29</xref>,<xref rid="B83-pharmaceutics-17-01216" ref-type="bibr">83</xref>]. Other neglected tropical diseases with zoonotic components, such as onchocerciasis and strongyloidiasis, could similarly benefit from the advancements in nanocarrier design (liposomes, nanoemulsions, SLNs) tailored for transdermal delivery of ivermectin, albendazole, or other relevant anthelmintics [<xref rid="B84-pharmaceutics-17-01216" ref-type="bibr">84</xref>,<xref rid="B85-pharmaceutics-17-01216" ref-type="bibr">85</xref>]. The core principles of overcoming the stratum corneum barrier, enhancing local drug concentration, enabling controlled release, and reducing systemic exposure are universally applicable. The success seen with leishmaniasis, malaria, and broad-spectrum drugs provides a strong foundation for expanding the application of this technology across the neglected zoonotic parasitic disease landscape.</p></sec></sec><sec id="sec4-pharmaceutics-17-01216"><title>4. Nanoformulations in Broad-Spectrum Antiparasitic Drugs</title><p>Beyond targeted therapies against specific pathogens (e.g., Leishmania, Plasmodium), nanoparticle-based transdermal delivery technologies have provided revolutionary solutions for enhancing the application of conventional broad-spectrum antiparasitic drugs. Taking avermectin and albendazole as examples, both exhibit high efficacy against a wide range of endo- and ectoparasites; however, their conventional administration routes, such as oral administration, are limited by low bioavailability, systemic toxicity, and poor patient compliance [<xref rid="B32-pharmaceutics-17-01216" ref-type="bibr">32</xref>,<xref rid="B40-pharmaceutics-17-01216" ref-type="bibr">40</xref>]. Nanoparticle-based reformulation significantly enhances transdermal permeation efficiency, targeting specificity, and therapeutic window of avermectin- and Benzimidazole-class drugs. We next review and discuss the updates related to nanoformulation-driven anthelmintic drugs (<xref rid="pharmaceutics-17-01216-t001" ref-type="table">Table 1</xref>).</p><sec id="sec4dot1-pharmaceutics-17-01216"><title>4.1. Avermectin-Class Drugs</title><p>Avermectin-class drugs such as avermectin, ivermectin and eprinomectin play an indispensable role in veterinary and human parasitic disease control due to their exceptional broad-spectrum antiparasitic activity [<xref rid="B91-pharmaceutics-17-01216" ref-type="bibr">91</xref>]. For instance, ivermectin represents a landmark therapeutic for treating onchocerciasis [<xref rid="B84-pharmaceutics-17-01216" ref-type="bibr">84</xref>], lymphatic filariasis [<xref rid="B92-pharmaceutics-17-01216" ref-type="bibr">92</xref>], scabies [<xref rid="B93-pharmaceutics-17-01216" ref-type="bibr">93</xref>], and strongyloidiasis [<xref rid="B85-pharmaceutics-17-01216" ref-type="bibr">85</xref>], and is included in the World Health Organization Essential Medicines List [<xref rid="B88-pharmaceutics-17-01216" ref-type="bibr">88</xref>]. However, they have long been constrained in their antiparasitic efficacy due to low solubility, insufficient transdermal permeation efficiency, and systemic toxicity risks [<xref rid="B88-pharmaceutics-17-01216" ref-type="bibr">88</xref>]. Multifaceted innovations in nanoparticle-based delivery technologies&#8212;through formulation design optimization and enhancement of controlled-release strategies&#8212;are progressively advancing their translation from laboratory research to clinical practice.</p><p>Early studies focused on solubility optimization and enhancement of the transdermal permeation efficiency of avermectin-class drugs. For instance, Das et al. pioneered a breakthrough with ivermectin-loaded microemulsion-based gel formulations using nanoscale technology, where in vitro membrane permeability assays demonstrated superior permeation advantages, enabling low-dose drugs to achieve equivalent or better efficacy compared to conventional formulations [<xref rid="B86-pharmaceutics-17-01216" ref-type="bibr">86</xref>]. Subsequently, an advanced ivermectin nanocrystal technology through nanocrystallization combined with lyophilization, achieved a 730-fold increase in equilibrium solubility, a 24-fold acceleration in dissolution rate, and threefold higher drug deposition in the deep dermis, significantly reducing side effect risks [<xref rid="B87-pharmaceutics-17-01216" ref-type="bibr">87</xref>]. Building upon these advancements, formulation diversity exploration has enabled tailored solutions for different infection scenarios. A recent study systematically compared three ivermectin-loaded formulations: nanoemulsion (NE), nanoemulsion gel (NEG), and colloidal system (CS) [<xref rid="B88-pharmaceutics-17-01216" ref-type="bibr">88</xref>]. NE exhibited the highest drug concentration at the stratum corneum and epidermis/dermis junction, making it ideal for localized therapy. NEG demonstrated superior adhesiveness, solubilization capacity, and occlusiveness, achieving the fastest delivery rate. CS showed the highest drug diffusion percentage, enabling efficient delivery via the follicular route at a 0.35% low dose (versus 2% in other systems) [<xref rid="B88-pharmaceutics-17-01216" ref-type="bibr">88</xref>]. This study not only highlights formulation design diversity but also provides a theoretical foundation for precision therapy by using conventional antiparasitic drugs (<xref rid="pharmaceutics-17-01216-f004" ref-type="fig">Figure 4</xref>).</p><p>To balance efficacy and safety of antiparasitic drugs, controlled-release technology has become a key research focus. Ivermectin-loaded solid lipid nanoparticles exhibiting excellent sustained-release efficacy, with their targeting capability significantly reducing systemic toxicity and side effects [<xref rid="B40-pharmaceutics-17-01216" ref-type="bibr">40</xref>]. With the acceleration of technology development, Mao et al. designed hybrid micelles that demonstrated 1.92-fold higher transdermal efficiency compared to the commercial pour-on formulation (Eprinex<sup>&#174;</sup>), and in vivo trials support its favorable safety profiles [<xref rid="B90-pharmaceutics-17-01216" ref-type="bibr">90</xref>]. In addition, the release profiles of mesoporous silica nanoparticles (IVM-MCM) and polymeric nanocapsules (IVM-NC) have been further studied. IVM-MCM facilitates rapid drug release suitable for acute infection management, whereas IVM-NC provides sustained release ideal for chronic prevention requirements [<xref rid="B89-pharmaceutics-17-01216" ref-type="bibr">89</xref>]. This rational optimization of ivermectin nanoformulations provides a novel strategy to accelerate its clinical translation [<xref rid="B89-pharmaceutics-17-01216" ref-type="bibr">89</xref>].</p><p>From solubility breakthroughs in microemulsion-based gels [<xref rid="B86-pharmaceutics-17-01216" ref-type="bibr">86</xref>] to transdermal optimization of hybrid micelles [<xref rid="B90-pharmaceutics-17-01216" ref-type="bibr">90</xref>], and from explorations in formulation diversity [<xref rid="B88-pharmaceutics-17-01216" ref-type="bibr">88</xref>] to the modulation of release kinetics [<xref rid="B40-pharmaceutics-17-01216" ref-type="bibr">40</xref>]. Avermectin-class nanoformulations are progressively overcoming some of the key limitations inherent in conventional formulations. However, their full clinical translation still requires overcoming barriers in manufacturing scalability, safety profiles, and therapeutic validation. Going forward, cross-disciplinary collaboration and technological innovation will be pivotal to translating the theoretical advantages of nanoformulations into practical clinical benefits for conventional anthelmintic drugs.</p><p>This figure illustrates the mechanism of ivermectin nanoemulsion (IVM-NE) in treating strongyloidiasis. IVM-NE, with favorable drug-release ability, releases ivermectin (IVM). IVM acts on glutamate-gated Cl<sup>&#8722;</sup> channels of Strongyloides organisms. It shows strong dermal retention, good safety, and is suitable for topical administration to combat strongyloidiasis.</p></sec><sec id="sec4dot2-pharmaceutics-17-01216"><title>4.2. Benzimidazole-Class Drugs</title><p>Benzimidazole-class drugs constitute the cornerstone of antihelminthic therapy [<xref rid="B94-pharmaceutics-17-01216" ref-type="bibr">94</xref>], exhibiting highly effective broad-spectrum activity against diverse intestinal nematodes, cestodes, and certain trematodes [<xref rid="B95-pharmaceutics-17-01216" ref-type="bibr">95</xref>]. However, oral formulations of conventional benzimidazoles are severely limited in antiparasitic efficacy and safety due to poor aqueous solubility (only 48.11 &#956;g/mL in PBS), significant first-pass metabolism (bioavailability of less than 5%), and hepatotoxicity induced by systemic exposure [<xref rid="B32-pharmaceutics-17-01216" ref-type="bibr">32</xref>]. Recent innovative strategies based on nanotechnology and transdermal delivery systems have successfully overcome these limitations, with key advancements manifested in the following aspects.</p><p>First, drug morphology reconstruction using carriers like solid lipid nanoparticles, the solubility kinetics of albendazole have been significantly improved. Permana et al. formulated albendazole into nanocrystals, achieving 89.92% cumulative drug release over 24 h in vitro with a 3.2-fold accelerated release rate [<xref rid="B81-pharmaceutics-17-01216" ref-type="bibr">81</xref>]. Similar to that, a polyethylene glycol reservoir stabilizes albendazole in an amorphous state, achieving a solubility of 283.62 &#956;g/mL, representing a 5-fold increase [<xref rid="B32-pharmaceutics-17-01216" ref-type="bibr">32</xref>]. Therefore, nanonization not only overcomes benzimidazole&#8217;s intrinsic hydrophobicity but also enables rapid therapeutic onset through accelerated dissolution.</p><p>Second, the application of dissolving microneedles (DMNs) and hydrogel-forming microneedles (HFM) has overcome skin barrier limitations, enabling precision drug delivery. Based on this nanoformulation, an albendazole-loaded dissolving microneedles-nanocrystals system achieved a penetration depth of 505.29 &#956;m in ex vivo porcine skin, with a peak dermal drug concentration of 1891.53 &#956;g/cm<sup>3</sup> [<xref rid="B81-pharmaceutics-17-01216" ref-type="bibr">81</xref>]. For albendazole sulfoxide delivered via a solid lipid nanoparticle&#8212;dissolving microneedle system, both drug targeting efficiency and direct transport percentage were significantly enhanced, reaching 11.99-fold and 91.66%, respectively [<xref rid="B83-pharmaceutics-17-01216" ref-type="bibr">83</xref>] (<xref rid="pharmaceutics-17-01216-f005" ref-type="fig">Figure 5</xref>). Additionally, the HFM-PEG integrated system delivering albendazole demonstrated a 24 h transdermal permeation of 4584.43 &#956;g/cm<sup>2</sup>&#8212;tens of times higher than oral formulations [<xref rid="B32-pharmaceutics-17-01216" ref-type="bibr">32</xref>]. Taken together, microneedle technology facilitates localized high-concentration exposure and lymphatic-targeted uptake, directly acting on parasite habitats (e.g., subcutaneous or lymphatic systems) while bypassing systemic metabolic losses.</p><p>Third, the sustained-release design of solid lipid nanoparticles and nanocrystals significantly prolongs drug action duration. Permana et al. demonstrated that the dissolving microneedles-nanocrystals system extended the drug half-life to 136 h (versus 3.54 h for oral nanocrystals) [<xref rid="B81-pharmaceutics-17-01216" ref-type="bibr">81</xref>]. The SLN-based system achieved 65.35% sustained release of albendazole sulfoxide (ABZ-OX) over 48 h, while reducing the generation of metabolite ABZ-ON by 65%. Furthermore, drug distribution levels in the liver and kidneys were only 27.5% and 44.5%, respectively, compared to the oral administration group [<xref rid="B83-pharmaceutics-17-01216" ref-type="bibr">83</xref>]. Mahfufah&#8217;s study further revealed that the nanosystem exhibited a hemolysis rate of less than 5%, maintained skin integrity, and a surface pH of 5.43&#8211;5.51, compatible with the physiological pH range, demonstrating significantly enhanced safety over conventional formulations [<xref rid="B32-pharmaceutics-17-01216" ref-type="bibr">32</xref>].</p><p>Collectively, nanotransdermal formulations for benzimidazole class drugs through a synergistic mechanism integrating &#8216;dissolution enhancement, delivery potentiation, and toxicity control&#8217; have achieved a breakthrough in both relative bioavailability and lymphatic targeting efficiency, providing highly effective, long-acting, and low-toxicity innovative solutions for cystic echinococcosis [<xref rid="B32-pharmaceutics-17-01216" ref-type="bibr">32</xref>,<xref rid="B81-pharmaceutics-17-01216" ref-type="bibr">81</xref>] and lymphatic filariasis [<xref rid="B83-pharmaceutics-17-01216" ref-type="bibr">83</xref>]. Future efforts should prioritize advancing clinical translation trials to evaluate the feasibility of scaled-up production and long-term safety profile.</p></sec></sec><sec id="sec5-pharmaceutics-17-01216"><title>5. Summary and Perspectives</title><p>Nanoparticle-based transdermal drug delivery systems, leveraging their unique delivery mechanisms and precisely controlled-release capabilities, have pioneered revolutionary pathways for antiparasitic drug development. Nanoformulations, including liposomes, nanoemulsions, and microneedles, nanocarriers overcome the physical barrier of the stratum corneum, significantly enhancing local drug permeation efficiency and targeting specificity, while decreasing first-pass metabolism and systemic toxicity associated with conventional administration routes. However, translating these promising nanoparticle-based formulations from laboratory research to clinical application still requires overcoming interrelated challenges in technology, production, and clinical translation.</p><p>Current challenges primarily revolve around the conflict between skin barrier penetration efficiency and targeting precision. The complex structure of the skin and the dynamic physiological microenvironment may compromise the stability of nanocarriers and their efficiency in achieving precise drug release. Moreover, the multi-stage life cycle and tissue tropism characteristics of parasites necessitate highly intelligent targeting strategies. Current environmentally responsive carriers, such as pH-sensitive systems, still face challenges in ensuring that their release kinetics fully align with the pathological microenvironmental fluctuations at the infection site.</p><p>Beyond technical performance, scalable manufacturing and rigorous safety evaluation remain significant bottlenecks. Issues such as batch-to-batch variability in encapsulation efficiency, insufficient long-term storage stability, and complex quality control standards pose major obstacles to industrial production. In resource-limited regions, high production costs and low-temperature storage requirements (e.g., lyophilization processes) further limit technological accessibility. Meanwhile, the long-term biosafety of nanomaterials remains incompletely characterized. Potential risks such as dermal irritation, immunogenicity, and systemic accumulation effects require validation through more comprehensive evaluation systems, including 3D skin models and computational toxicology.</p><p>Most critically, its clinical translation and commercialization pathway still require substantial refinement, particularly in providing more detailed evidence regarding clinical trials, regulatory approval, and economic viability. The current evidence base is primarily built on in vitro and preclinical animal studies, while large-scale clinical trial data necessary for advancing to clinical application remain scarce. The regulatory approval pathway for nanomedicines is complex and lacks a fully standardized framework, requiring comprehensive characterization and strict review by agencies such as the FDA and EMA regarding the in vivo behavior, stability, and potential toxicity of nanoformulations. Finally, economic viability is crucial in determining its accessibility. The high costs associated with complex materials, sophisticated manufacturing processes, and potential cold-chain storage requirements hinder the application of this technology in low-income regions where it is most needed.</p><p>The underlying root cause of the aforementioned economic feasibility challenges lies in a core contradiction within the public health domain. While malaria and leishmaniasis receive prioritized support from international organizations, nanopharmaceutical research and development for most neglected tropical diseases (NTDs) (e.g., onchocerciasis, schistosomiasis) remains reliant on non-profit funding with weak commercial drivers. Strategically leveraging policy instruments (e.g., the Medicines Patent Pool, MPP) and regional collaborations to reduce costs, coupled with advancing generic drug manufacturing at scale, has become pivotal to achieving equitable technological accessibility.</p><p>Therefore, to systematically address the multi-faceted challenges described above, it requires not only continuous innovation in fundamental research but also hinges critically on the rational selection of nanoplatforms tailored to specific application contexts. For instance, functionalized liposomes and transfersomes, with their superior intracellular delivery capabilities, tend to be the preferred candidates for managing intracellular infections like leishmaniasis. In contrast, for broad-spectrum anthelmintics that require high-dose and long-term administration, scalable nanoemulsions or sustained-release nanocrystals may offer more practical advantages due to their manufacturing feasibility. Meanwhile, microneedle technology holds unique potential for one-off vaccination or precise lymphatic targeting applications, albeit at a higher unit cost. This strategic selection process itself is a critical step toward viable applications.</p><p>Looking forward, breakthroughs in nanotechnology-based transdermal drug delivery systems will require multidimensional innovation strategies. At the scientific frontier, the development of bioinspired nanocarriers (e.g., parasite membrane-camouflaged systems) and intelligent responsive materials (e.g., thermo/enzyme-sensitive hydrogels) holds promise for achieving spatiotemporal dynamic drug release. The integration of microneedle arrays with nanotechnology could mechanically breach the skin barrier while enabling precise modulation of drug release kinetics. Technologically, artificial intelligence (AI)-driven carrier design (e.g., machine learning-optimized lipid compositions) and modular manufacturing processes (e.g., microfluidic continuous-flow technology) are expected to significantly shorten research and development cycles and reduce costs. Furthermore, advancing the global health governance framework&#8212;particularly through the &#8220;One Health&#8221; initiative&#8212;could accelerate technology translation via public&#8211;private partnerships, while developing region-adapted formulations (e.g., prefilled microneedle patches) for low-resource settings.</p><p>Transdermal delivery of nanoformulation represents not merely a technological innovation but a critical practice in advancing global health equity. Only by overcoming the systemic barriers among penetration efficiency, targeting precision, manufacturing feasibility, and health policy alignment can we translate this potential into life-saving therapeutics, ultimately advancing the vision of the elimination of neglected tropical diseases.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank the BioRender team (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.biorender.com">www.biorender.com</uri>) for providing elements in for drawing schematic diagrams.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, X.G. and Z.G.; Formal analysis, J.W.; Data curation, Y.Z., R.X. and C.W.; Investigation, Y.Z. and R.X.; writing&#8212;original draft preparation, Y.Z., R.X. and X.G.; visualization, R.X.; writing&#8212;review and editing, C.W., J.W., D.G., W.L., S.J., Z.G. and X.G.; Validation, D.G., W.L., Z.G. and X.G.; Supervision, S.J., Z.G. and X.G.; funding acquisition, Z.G. and X.G.; All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created during the writing of this review article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-01216"><label>1.</label><element-citation publication-type="webpage"><article-title>Global Report on Neglected Tropical Diseases 2024</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/teams/control-of-neglected-tropical-diseases/global-report-on-neglected-tropical-diseases-2024" ext-link-type="uri">https://www.who.int/teams/control-of-neglected-tropical-diseases/global-report-on-neglected-tropical-diseases-2024</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-01">(accessed on 1 May 2025)</date-in-citation></element-citation></ref><ref id="B2-pharmaceutics-17-01216"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otranto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Strube</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L.</given-names></name></person-group><article-title>Zoonotic Parasites: The One Health Challenge</article-title><source>Parasitol. Res.</source><year>2021</year><volume>120</volume><fpage>4073</fpage><lpage>4074</lpage><pub-id pub-id-type="doi">10.1007/s00436-021-07221-9</pub-id><pub-id pub-id-type="pmid">34142224</pub-id><pub-id pub-id-type="pmcid">PMC8211557</pub-id></element-citation></ref><ref id="B3-pharmaceutics-17-01216"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sokolow</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Lafferty</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Kuris</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Rickards</surname><given-names>C.</given-names></name><name name-style="western"><surname>De Leo</surname><given-names>G.A.</given-names></name></person-group><article-title>Global Assessment of Schistosomiasis Control Over the Past Century Shows Targeting the Snail Intermediate Host Works Best</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><elocation-id>e0004794</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004794</pub-id><pub-id pub-id-type="pmid">27441556</pub-id><pub-id pub-id-type="pmcid">PMC4956325</pub-id></element-citation></ref><ref id="B4-pharmaceutics-17-01216"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alkilani</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>McCrudden</surname><given-names>M.T.C.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name></person-group><article-title>Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the Stratum Corneum</article-title><source>Pharmaceutics</source><year>2015</year><volume>7</volume><fpage>438</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.3390/pharmaceutics7040438</pub-id><pub-id pub-id-type="pmid">26506371</pub-id><pub-id pub-id-type="pmcid">PMC4695828</pub-id></element-citation></ref><ref id="B5-pharmaceutics-17-01216"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruno</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>C.S.</given-names></name></person-group><article-title>Basics and Recent Advances in Peptide and Protein Drug Delivery</article-title><source>Ther. Deliv.</source><year>2013</year><volume>4</volume><fpage>1443</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.4155/tde.13.104</pub-id><pub-id pub-id-type="pmid">24228993</pub-id><pub-id pub-id-type="pmcid">PMC3956587</pub-id></element-citation></ref><ref id="B6-pharmaceutics-17-01216"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patlolla</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Belay</surname><given-names>K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.S.</given-names></name></person-group><article-title>Trans Location of Cell Penetrating Peptide Engrafted Nanoparticles across Skin Layers</article-title><source>Biomaterials</source><year>2010</year><volume>31</volume><fpage>5598</fpage><lpage>5607</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.03.010</pub-id><pub-id pub-id-type="pmid">20413152</pub-id><pub-id pub-id-type="pmcid">PMC2875303</pub-id></element-citation></ref><ref id="B7-pharmaceutics-17-01216"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashtikar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Langel&#252;ddecke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fahr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deckert</surname><given-names>V.</given-names></name></person-group><article-title>Tip-Enhanced Raman Scattering for Tracking of Invasomes in the Stratum Corneum</article-title><source>Biochim. Biophys. Acta (BBA)&#8212;Gen. Subj.</source><year>2017</year><volume>1861</volume><fpage>2630</fpage><lpage>2639</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2017.07.003</pub-id><pub-id pub-id-type="pmid">28689988</pub-id></element-citation></ref><ref id="B8-pharmaceutics-17-01216"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoellhammer</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Blankschtein</surname><given-names>D.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name></person-group><article-title>Skin Permeabilization for Transdermal Drug Delivery: Recent Advances and Future Prospects</article-title><source>Expert Opin. Drug Deliv.</source><year>2014</year><volume>11</volume><fpage>393</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1517/17425247.2014.875528</pub-id><pub-id pub-id-type="pmid">24392787</pub-id><pub-id pub-id-type="pmcid">PMC3980659</pub-id></element-citation></ref><ref id="B9-pharmaceutics-17-01216"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pradhan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pradhan</surname><given-names>O.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>Nano-Formulations for Transdermal Drug Delivery: A Review</article-title><source>Chin. Chem. Lett.</source><year>2018</year><volume>29</volume><fpage>1713</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1016/j.cclet.2018.10.037</pub-id></element-citation></ref><ref id="B10-pharmaceutics-17-01216"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name></person-group><article-title>Nanotechnology-Based Strategies for Treatment of Ocular Disease</article-title><source>Acta Pharm. Sin. B</source><year>2017</year><volume>7</volume><fpage>281</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2016.09.001</pub-id><pub-id pub-id-type="pmid">28540165</pub-id><pub-id pub-id-type="pmcid">PMC5430571</pub-id></element-citation></ref><ref id="B11-pharmaceutics-17-01216"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayser</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kiderlen</surname><given-names>A.F.</given-names></name></person-group><article-title>Delivery Strategies for Antiparasitics</article-title><source>Expert Opin. Investig. Drugs</source><year>2003</year><volume>12</volume><fpage>197</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1517/13543784.12.2.197</pub-id><pub-id pub-id-type="pmid">12556214</pub-id></element-citation></ref><ref id="B12-pharmaceutics-17-01216"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laouini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Charcosset</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fessi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Holdich</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Vladisavljevi&#263;</surname><given-names>G.T.</given-names></name></person-group><article-title>Preparation of Liposomes: A Novel Application of Microengineered Membranes-From Laboratory Scale to Large Scale</article-title><source>Colloids Surf. B Biointerfaces</source><year>2013</year><volume>112</volume><fpage>272</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2013.07.066</pub-id><pub-id pub-id-type="pmid">23999143</pub-id></element-citation></ref><ref id="B13-pharmaceutics-17-01216"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ishibashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>Y.</given-names></name></person-group><article-title>Effect of Egg Yolk Lecithin on Transdermal Delivery of Bunazosin Hydrochloride</article-title><source>J. Pharm. Pharmacol.</source><year>1987</year><volume>39</volume><fpage>399</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.1987.tb03407.x</pub-id><pub-id pub-id-type="pmid">2886592</pub-id></element-citation></ref><ref id="B14-pharmaceutics-17-01216"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirjavainen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Urtti</surname><given-names>A.</given-names></name><name name-style="western"><surname>J&#228;&#228;skel&#228;inen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Marjukka Suhonen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Paronen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Valjakka-Koskela</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kiesvaara</surname><given-names>J.</given-names></name><name name-style="western"><surname>M&#246;nkk&#246;nen</surname><given-names>J.</given-names></name></person-group><article-title>Interaction of Liposomes with Human Skin In Vitro&#8212;The Influence of Lipid Composition and Structure</article-title><source>Biochim. Biophys. Acta (BBA)&#8212;Lipids Lipid Metab.</source><year>1996</year><volume>1304</volume><fpage>179</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/S0005-2760(96)00126-9</pub-id><pub-id pub-id-type="pmid">8982264</pub-id></element-citation></ref><ref id="B15-pharmaceutics-17-01216"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirjavainen</surname><given-names>M.</given-names></name><name name-style="western"><surname>M&#246;nkk&#246;nen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saukkosaari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valjakka-Koskela</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kiesvaara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Urtti</surname><given-names>A.</given-names></name></person-group><article-title>Phospholipids Affect Stratum Corneum Lipid Bilayer Fluidity and Drug Partitioning into the Bilayers</article-title><source>J. Control. Release</source><year>1999</year><volume>58</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/S0168-3659(98)00152-7</pub-id><pub-id pub-id-type="pmid">10053193</pub-id></element-citation></ref><ref id="B16-pharmaceutics-17-01216"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Maghraby</surname><given-names>G.M.M.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>B.W.</given-names></name></person-group><article-title>Can Drug-Bearing Liposomes Penetrate Intact Skin?</article-title><source>J. Pharm. Pharmacol.</source><year>2006</year><volume>58</volume><fpage>415</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1211/jpp.58.4.0001</pub-id><pub-id pub-id-type="pmid">16597359</pub-id></element-citation></ref><ref id="B17-pharmaceutics-17-01216"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akram</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Jamshaid</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>F.U.</given-names></name><name name-style="western"><surname>Zaeem</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Zeb</surname><given-names>A.</given-names></name></person-group><article-title>Transfersomes: A Revolutionary Nanosystem for Efficient Transdermal Drug Delivery</article-title><source>AAPS PharmSciTech</source><year>2021</year><volume>23</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1208/s12249-021-02166-9</pub-id><pub-id pub-id-type="pmid">34853906</pub-id></element-citation></ref><ref id="B18-pharmaceutics-17-01216"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sala</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diab</surname><given-names>R.</given-names></name><name name-style="western"><surname>Elaissari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fessi</surname><given-names>H.</given-names></name></person-group><article-title>Lipid Nanocarriers as Skin Drug Delivery Systems: Properties, Mechanisms of Skin Interactions and Medical Applications</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>535</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.10.046</pub-id><pub-id pub-id-type="pmid">29111097</pub-id></element-citation></ref><ref id="B19-pharmaceutics-17-01216"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sarath</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Anoop</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Ivon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nazeera</surname><given-names>F.N.M.</given-names></name><name name-style="western"><surname>Neethu</surname><given-names>N.P.P.</given-names></name></person-group><article-title>Lipid-Based Vesicles: A Non-Invasive Tool for Transdermal Drug Delivery</article-title><source>J. Pharm. Innov.</source><year>2022</year><volume>17</volume><fpage>1039</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1007/s12247-021-09572-3</pub-id></element-citation></ref><ref id="B20-pharmaceutics-17-01216"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>A.U.</given-names></name><name name-style="western"><surname>Jamshaid</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ud Din</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zeb</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>G.M.</given-names></name></person-group><article-title>Designing, Optimization and Characterization of Trifluralin Transfersomal Gel to Passively Target Cutaneous Leishmaniasis</article-title><source>J. Pharm. Sci.</source><year>2022</year><volume>111</volume><fpage>1798</fpage><lpage>1811</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2022.01.010</pub-id><pub-id pub-id-type="pmid">35081406</pub-id></element-citation></ref><ref id="B21-pharmaceutics-17-01216"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bashir</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shabbir</surname><given-names>K.</given-names></name><name name-style="western"><surname>Din</surname><given-names>F.U.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>G.M.</given-names></name></person-group><article-title>Nitazoxanide and Quercetin Co-Loaded Nanotransfersomal Gel for Topical Treatment of Cutaneous Leishmaniasis with Macrophage Targeting and Enhanced Anti-Leishmanial Effect</article-title><source>Heliyon</source><year>2023</year><volume>9</volume><fpage>e21939</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e21939</pub-id><pub-id pub-id-type="pmid">38027656</pub-id><pub-id pub-id-type="pmcid">PMC10661431</pub-id></element-citation></ref><ref id="B22-pharmaceutics-17-01216"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.-Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.-S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>M.-B.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>A.-H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>L.-H.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Z.-G.</given-names></name></person-group><article-title>Compound Antimalarial Ethosomal Cataplasm: Preparation, Evaluation, and Mechanism of Penetration Enhancement</article-title><source>Int. J. Nanomed.</source><year>2015</year><volume>10</volume><fpage>4239</fpage><lpage>4253</lpage><pub-id pub-id-type="doi">10.2147/IJN.S83402</pub-id><pub-id pub-id-type="pmid">26170661</pub-id><pub-id pub-id-type="pmcid">PMC4494185</pub-id></element-citation></ref><ref id="B23-pharmaceutics-17-01216"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naseema</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kovooru</surname><given-names>L.</given-names></name><name name-style="western"><surname>Behera</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>K.P.P.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>P.</given-names></name></person-group><article-title>A Critical Review of Synthesis Procedures, Applications and Future Potential of Nanoemulsions</article-title><source>Adv. Colloid. Interface Sci.</source><year>2021</year><volume>287</volume><fpage>102318</fpage><pub-id pub-id-type="doi">10.1016/j.cis.2020.102318</pub-id><pub-id pub-id-type="pmid">33242713</pub-id></element-citation></ref><ref id="B24-pharmaceutics-17-01216"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sghier</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mur</surname><given-names>M.</given-names></name><name name-style="western"><surname>Veiga</surname><given-names>F.</given-names></name><name name-style="western"><surname>Paiva-Santos</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Pires</surname><given-names>P.C.</given-names></name></person-group><article-title>Novel Therapeutic Hybrid Systems Using Hydrogels and Nanotechnology: A Focus on Nanoemulgels for the Treatment of Skin Diseases</article-title><source>Gels</source><year>2024</year><volume>10</volume><elocation-id>45</elocation-id><pub-id pub-id-type="doi">10.3390/gels10010045</pub-id><pub-id pub-id-type="pmid">38247768</pub-id><pub-id pub-id-type="pmcid">PMC10815052</pub-id></element-citation></ref><ref id="B25-pharmaceutics-17-01216"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coelho</surname><given-names>D.</given-names></name><name name-style="western"><surname>Veleirinho</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mazzarino</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alberti</surname><given-names>T.</given-names></name><name name-style="western"><surname>Buzanello</surname><given-names>E.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Yunes</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Steindel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maraschin</surname><given-names>M.</given-names></name></person-group><article-title>Polyvinyl Alcohol-Based Electrospun Matrix as a Delivery System for Nanoemulsion Containing Chalcone against Leishmania (Leishmania) Amazonensis</article-title><source>Colloids Surf. B Biointerfaces</source><year>2021</year><volume>198</volume><elocation-id>111390</elocation-id><pub-id pub-id-type="doi">10.1016/j.colsurfb.2020.111390</pub-id><pub-id pub-id-type="pmid">33208279</pub-id></element-citation></ref><ref id="B26-pharmaceutics-17-01216"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Fernandez-Culma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Upegui</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Rios-Vasquez</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Quinones</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ocampo-Cardona</surname><given-names>R.</given-names></name><name name-style="western"><surname>Echeverri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Velez</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Robledo</surname><given-names>S.M.</given-names></name></person-group><article-title>Nanoemulsions for Increased Penetrability and Sustained Release of Leishmanicidal Compounds</article-title><source>Arch. Pharm.</source><year>2023</year><volume>356</volume><fpage>e202300108</fpage><pub-id pub-id-type="doi">10.1002/ardp.202300108</pub-id><pub-id pub-id-type="pmid">37068175</pub-id></element-citation></ref><ref id="B27-pharmaceutics-17-01216"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Han</surname><given-names>M.-R.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.-H.</given-names></name></person-group><article-title>Polymer Microneedles for Transdermal Drug Delivery</article-title><source>J. Drug Target.</source><year>2013</year><volume>21</volume><fpage>211</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.3109/1061186X.2012.741136</pub-id><pub-id pub-id-type="pmid">23167609</pub-id></element-citation></ref><ref id="B28-pharmaceutics-17-01216"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gou</surname><given-names>M.</given-names></name></person-group><article-title>3D-Printed Microneedle Arrays for Drug Delivery</article-title><source>J. Control. Release</source><year>2022</year><volume>350</volume><fpage>933</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.08.022</pub-id><pub-id pub-id-type="pmid">35977583</pub-id></element-citation></ref><ref id="B29-pharmaceutics-17-01216"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunawan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bestari</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Ramadon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Efendi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boonkanokwong</surname><given-names>V.</given-names></name></person-group><article-title>Combination of Lipid-Based Nanoparticles with Microneedles as a Promising Strategy for Enhanced Transdermal Delivery Systems: A Comprehensive Review</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2025</year><volume>107</volume><fpage>106807</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2025.106807</pub-id></element-citation></ref><ref id="B30-pharmaceutics-17-01216"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumitriu Buzia</surname><given-names>O.</given-names></name><name name-style="western"><surname>P&#259;duraru</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Stefan</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Dinu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coco&#537;</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Nwabudike</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Tatu</surname><given-names>A.L.</given-names></name></person-group><article-title>Strategies for Improving Transdermal Administration: New Approaches to Controlled Drug Release</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>1183</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15041183</pub-id><pub-id pub-id-type="pmid">37111667</pub-id><pub-id pub-id-type="pmcid">PMC10143057</pub-id></element-citation></ref><ref id="B31-pharmaceutics-17-01216"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zare</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Khorram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barzegar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sarkari</surname><given-names>B.</given-names></name><name name-style="western"><surname>Asgari</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ahadian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zomorodian</surname><given-names>K.</given-names></name></person-group><article-title>Dissolvable Carboxymethyl Cellulose/Polyvinylpyrrolidone Microneedle Arrays for Transdermal Delivery of Amphotericin B to Treat Cutaneous Leishmaniasis</article-title><source>Int. J. Biol. Macromol.</source><year>2021</year><volume>182</volume><fpage>1310</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.05.075</pub-id><pub-id pub-id-type="pmid">34000308</pub-id></element-citation></ref><ref id="B32-pharmaceutics-17-01216"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahfufah</surname><given-names>U.</given-names></name><name name-style="western"><surname>Fitri Sultan</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Nurul Fitri</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Elim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sya&#8217;ban Mahfud</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Wafiah</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ardita Friandini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chabib</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aliyah Permana</surname><given-names>A.D.</given-names></name></person-group><article-title>Application of Multipolymers System in the Development of Hydrogel-Forming Microneedle Integrated with Polyethylene Glycol Reservoir for Transdermal Delivery of Albendazole</article-title><source>Eur. Polym. J.</source><year>2023</year><volume>183</volume><fpage>111762</fpage><pub-id pub-id-type="doi">10.1016/j.eurpolymj.2022.111762</pub-id></element-citation></ref><ref id="B33-pharmaceutics-17-01216"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rawat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bohidar</surname><given-names>H.B.</given-names></name></person-group><article-title>Role of Nanomedicines in Controlling Malaria: A Review</article-title><source>Curr. Top. Med. Chem.</source><year>2023</year><volume>23</volume><fpage>1477</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.2174/1568026623666230417083401</pub-id><pub-id pub-id-type="pmid">37073152</pub-id></element-citation></ref><ref id="B34-pharmaceutics-17-01216"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nahanji</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Mahboobian</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Harchegani</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Mohebali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fallah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nourian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Motavallihaghi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maghsood</surname><given-names>A.H.</given-names></name></person-group><article-title>Enhancing the Efficacy of Fluconazole against Leishmania Major: Formulation and Evaluation of FLZ-Nanoemulsions for Topical Delivery</article-title><source>Biomed. Pharmacother.</source><year>2024</year><volume>178</volume><elocation-id>117109</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2024.117109</pub-id><pub-id pub-id-type="pmid">39024835</pub-id></element-citation></ref><ref id="B35-pharmaceutics-17-01216"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deshmukh</surname><given-names>R.</given-names></name></person-group><article-title>Exploring the Potential of Antimalarial Nanocarriers as a Novel Therapeutic Approach</article-title><source>J. Mol. Graph. Model.</source><year>2023</year><volume>122</volume><fpage>108497</fpage><pub-id pub-id-type="doi">10.1016/j.jmgm.2023.108497</pub-id><pub-id pub-id-type="pmid">37149980</pub-id></element-citation></ref><ref id="B36-pharmaceutics-17-01216"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nemati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mottaghi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karami</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mirjalali</surname><given-names>H.</given-names></name></person-group><article-title>Development of Solid Lipid Nanoparticles-Loaded Drugs in Parasitic Diseases</article-title><source>Discov. Nano</source><year>2024</year><volume>19</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s11671-023-03955-w</pub-id><pub-id pub-id-type="pmid">38175309</pub-id><pub-id pub-id-type="pmcid">PMC10767167</pub-id></element-citation></ref><ref id="B37-pharmaceutics-17-01216"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Osman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sadozai</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>I.</given-names></name></person-group><article-title>Ameliorated Delivery of Amphotericin B to Macrophages Using Chondroitin Sulfate Surface-Modified Liposome Nanoparticles</article-title><source>Drug Dev. Ind. Pharm.</source><year>2025</year><volume>51</volume><fpage>38</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1080/03639045.2024.2443007</pub-id><pub-id pub-id-type="pmid">39679495</pub-id></element-citation></ref><ref id="B38-pharmaceutics-17-01216"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aderibigbe</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sadiku</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jayaramudu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sinha Ray</surname><given-names>S.</given-names></name></person-group><article-title>Controlled Dual Release Study of Curcumin and a 4-aminoquinoline Analog from Gum Acacia Containing Hydrogels</article-title><source>J. Appl. Polym. Sci.</source><year>2015</year><volume>132</volume><fpage>app.41613</fpage><pub-id pub-id-type="doi">10.1002/app.41613</pub-id></element-citation></ref><ref id="B39-pharmaceutics-17-01216"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aderibigbe</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Mhlwatika</surname><given-names>Z.</given-names></name></person-group><article-title>Dual Release Kinetics of Antimalarials from Soy Protein Isolate-Carbopol-Polyacrylamide Based Hydrogels</article-title><source>J. Appl. Polym. Sci.</source><year>2016</year><volume>133</volume><fpage>43918</fpage><pub-id pub-id-type="doi">10.1002/app.43918</pub-id></element-citation></ref><ref id="B40-pharmaceutics-17-01216"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bhutto</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Ivermection-Loaded Solid Lipid Nanoparticles: Preparation, Characterisation, Stability and Transdermal Behaviour</article-title><source>Artif. Cells Nanomed. Biotechnol.</source><year>2018</year><volume>46</volume><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1080/21691401.2017.1307207</pub-id><pub-id pub-id-type="pmid">28368657</pub-id></element-citation></ref><ref id="B41-pharmaceutics-17-01216"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahimi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seyyed Tabaei</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Ziai</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Sadri</surname><given-names>M.</given-names></name></person-group><article-title>Anti-Leishmanial Effects of Chitosan-Polyethylene Oxide Nanofibers Containing Berberine: An Applied Model for Leishmania Wound Dressing</article-title><source>Iran. J. Med. Sci.</source><year>2020</year><volume>45</volume><fpage>286</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.30476/IJMS.2019.45784</pub-id><pub-id pub-id-type="pmid">32801418</pub-id><pub-id pub-id-type="pmcid">PMC7395954</pub-id></element-citation></ref><ref id="B42-pharmaceutics-17-01216"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seyyed Tabaei</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Rahimi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akbaribazm</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ziai</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Sadri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shahrokhi</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>M.S.</given-names></name></person-group><article-title>Chitosan-Based Nano-Scaffolds as Antileishmanial Wound Dressing in BALB/c Mice Treatment: Characterization and Design of Tissue Regeneration</article-title><source>Iran. J. Basic. Med. Sci.</source><year>2020</year><volume>23</volume><fpage>788</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.22038/ijbms.2020.41361.9770</pub-id><pub-id pub-id-type="pmid">32695296</pub-id><pub-id pub-id-type="pmcid">PMC7351439</pub-id></element-citation></ref><ref id="B43-pharmaceutics-17-01216"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golshirazi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohammadzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Labbaf</surname><given-names>S.</given-names></name></person-group><article-title>The Synergistic Potential of Hydrogel Microneedles and Nanomaterials: Breaking Barriers in Transdermal Therapy</article-title><source>Macromol. Biosci.</source><year>2025</year><volume>25</volume><elocation-id>2400228</elocation-id><pub-id pub-id-type="doi">10.1002/mabi.202400228</pub-id><pub-id pub-id-type="pmid">39195571</pub-id></element-citation></ref><ref id="B44-pharmaceutics-17-01216"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alex</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alsawaftah</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Husseini</surname><given-names>G.A.</given-names></name></person-group><article-title>State-of-All-the-Art and Prospective Hydrogel-Based Transdermal Drug Delivery Systems</article-title><source>Appl. Sci.</source><year>2024</year><volume>14</volume><elocation-id>2926</elocation-id><pub-id pub-id-type="doi">10.3390/app14072926</pub-id></element-citation></ref><ref id="B45-pharmaceutics-17-01216"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dehghani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Farhadian</surname><given-names>N.</given-names></name><name name-style="western"><surname>Goyonlo</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>O.</given-names></name></person-group><article-title>A Novel Topical Formulation of the Leishmaniasis Drug Glucantime as a Nanostructured Lipid Carrier-Based Hydrogel</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2023</year><volume>109</volume><fpage>301</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.23-0116</pub-id><pub-id pub-id-type="pmid">37308100</pub-id><pub-id pub-id-type="pmcid">PMC10397459</pub-id></element-citation></ref><ref id="B46-pharmaceutics-17-01216"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khaleeq</surname><given-names>N.</given-names></name><name name-style="western"><surname>Batool</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dar</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Din</surname><given-names>F.-U.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>G.M.</given-names></name></person-group><article-title>Rifampicin-Loaded Nanotransferosomal Gel for Treatment of Cutaneous Leishmaniasis: Passive Targeting Via Topical Route</article-title><source>Nanomedicine</source><year>2020</year><volume>15</volume><fpage>183</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.2217/nnm-2019-0320</pub-id><pub-id pub-id-type="pmid">31916472</pub-id></element-citation></ref><ref id="B47-pharmaceutics-17-01216"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyagi</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Jadon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sahu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Katare</surname><given-names>O.P.</given-names></name><name name-style="western"><surname>Dalai</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Awasthi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marepally</surname><given-names>S.K.</given-names></name></person-group><article-title>Elastic Liposome-Mediated Transdermal Immunization Enhanced the Immunogenicity of P. Falciparum Surface Antigen, MSP-119</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>4630</fpage><lpage>4638</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.06.054</pub-id><pub-id pub-id-type="pmid">26141014</pub-id></element-citation></ref><ref id="B48-pharmaceutics-17-01216"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyagi</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Dalai</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Awasthi</surname><given-names>A.</given-names></name></person-group><article-title>Transdermal Immunization of P-Falciparum Surface Antigen (MSP-1<sub>19</sub>) via Elastic Liposomes Confers Robust Immunogenicity</article-title><source>Hum. Vaccines Immunother.</source><year>2016</year><volume>12</volume><fpage>990</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1116656</pub-id><pub-id pub-id-type="pmcid">PMC4962934</pub-id><pub-id pub-id-type="pmid">26810033</pub-id></element-citation></ref><ref id="B49-pharmaceutics-17-01216"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puttappa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Yamjala</surname><given-names>K.</given-names></name></person-group><article-title>Artesunate-Quercetin/Luteolin Dual Drug Nanofacilitated Synergistic Treatment for Malaria: A Plausible Approach to Overcome Artemisinin Combination Therapy Resistance</article-title><source>Med. Hypotheses</source><year>2017</year><volume>109</volume><fpage>176</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2017.10.016</pub-id><pub-id pub-id-type="pmid">29150282</pub-id></element-citation></ref><ref id="B50-pharmaceutics-17-01216"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Courtenay</surname><given-names>O.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Bern</surname><given-names>C.</given-names></name></person-group><article-title>Combining Epidemiology with Basic Biology of Sand Flies, Parasites, and Hosts to Inform Leishmaniasis Transmission Dynamics and Control</article-title><source>PLoS Pathog.</source><year>2017</year><volume>13</volume><elocation-id>e1006571</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006571</pub-id><pub-id pub-id-type="pmid">29049371</pub-id><pub-id pub-id-type="pmcid">PMC5648254</pub-id></element-citation></ref><ref id="B51-pharmaceutics-17-01216"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burza</surname><given-names>S.</given-names></name><name name-style="western"><surname>Croft</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Boelaert</surname><given-names>M.</given-names></name></person-group><article-title>Leishmaniasis</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>951</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31204-2</pub-id><pub-id pub-id-type="pmid">30126638</pub-id></element-citation></ref><ref id="B52-pharmaceutics-17-01216"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Assche</surname><given-names>T.</given-names></name><name name-style="western"><surname>Deschacht</surname><given-names>M.</given-names></name><name name-style="western"><surname>da Luz</surname><given-names>R.A.I.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cos</surname><given-names>P.</given-names></name></person-group><article-title><italic toggle="yes">Leishmania</italic>&#8211;Macrophage Interactions: Insights into the Redox Biology</article-title><source>Free Radic. Biol. Med.</source><year>2011</year><volume>51</volume><fpage>337</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2011.05.011</pub-id><pub-id pub-id-type="pmid">21620959</pub-id></element-citation></ref><ref id="B53-pharmaceutics-17-01216"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussain</surname><given-names>H.</given-names></name><name name-style="western"><surname>Al-Harrasi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Rawahi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Green</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>S.</given-names></name></person-group><article-title>Fruitful Decade for Antileishmanial Compounds from 2002 to Late 2011</article-title><source>Chem. Rev.</source><year>2014</year><volume>114</volume><fpage>10369</fpage><lpage>10428</lpage><pub-id pub-id-type="doi">10.1021/cr400552x</pub-id><pub-id pub-id-type="pmid">25253511</pub-id></element-citation></ref><ref id="B54-pharmaceutics-17-01216"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reithinger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dujardin</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Louzir</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pirmez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brooker</surname><given-names>S.</given-names></name></person-group><article-title>Cutaneous Leishmaniasis</article-title><source>Lancet Infect. Dis.</source><year>2007</year><volume>7</volume><fpage>581</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(07)70209-8</pub-id><pub-id pub-id-type="pmid">17714672</pub-id></element-citation></ref><ref id="B55-pharmaceutics-17-01216"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olliaro</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Guerin</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Gerstl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haaskjold</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Rottingen</surname><given-names>J.-A.</given-names></name><name name-style="western"><surname>Sundar</surname><given-names>S.</given-names></name></person-group><article-title>Treatment Options for Visceral Leishmaniasis: A Systematic Review of Clinical Studies Done in India, 1980&#8211;2004</article-title><source>Lancet Infect. Dis.</source><year>2005</year><volume>5</volume><fpage>763</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(05)70296-6</pub-id><pub-id pub-id-type="pmid">16310148</pub-id></element-citation></ref><ref id="B56-pharmaceutics-17-01216"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chakravarty</surname><given-names>J.</given-names></name></person-group><article-title>An Update on Pharmacotherapy for Leishmaniasis</article-title><source>Expert Opin. Pharmacother.</source><year>2015</year><volume>16</volume><fpage>237</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1517/14656566.2015.973850</pub-id><pub-id pub-id-type="pmid">25346016</pub-id><pub-id pub-id-type="pmcid">PMC4293334</pub-id></element-citation></ref><ref id="B57-pharmaceutics-17-01216"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varma</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Redding</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Bachelder</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>K.M.</given-names></name></person-group><article-title>Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis</article-title><source>ACS Biomater. Sci. Eng.</source><year>2021</year><volume>7</volume><fpage>1725</fpage><lpage>1741</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.0c01132</pub-id><pub-id pub-id-type="pmid">33966377</pub-id><pub-id pub-id-type="pmcid">PMC10372633</pub-id></element-citation></ref><ref id="B58-pharmaceutics-17-01216"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riaz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.F.A.</given-names></name><name name-style="western"><surname>Jalil</surname><given-names>A.</given-names></name><name name-style="western"><surname>ur Rehman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mubarak</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Parhizkar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Muqaddas</surname><given-names>H.</given-names></name></person-group><article-title>Lipid-Based Nanocarriers for Topical Therapy of Cutaneous Leishmaniasis: An Insight into the Mechanism of Action</article-title><source>ACS Omega</source><year>2025</year><volume>10</volume><fpage>23873</fpage><lpage>23888</lpage><pub-id pub-id-type="doi">10.1021/acsomega.5c00046</pub-id><pub-id pub-id-type="pmid">40547705</pub-id><pub-id pub-id-type="pmcid">PMC12177655</pub-id></element-citation></ref><ref id="B59-pharmaceutics-17-01216"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romero</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Sabino</surname><given-names>M.A.</given-names></name></person-group><article-title>Application of Nano and Microformulations to Improve the Leishmanicidal Response of Quinoline Compounds: A Brief Review</article-title><source>Front. Chem.</source><year>2025</year><volume>13</volume><elocation-id>1622566</elocation-id><pub-id pub-id-type="doi">10.3389/fchem.2025.1622566</pub-id><pub-id pub-id-type="pmid">40785709</pub-id><pub-id pub-id-type="pmcid">PMC12331655</pub-id></element-citation></ref><ref id="B60-pharmaceutics-17-01216"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Souza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marins</surname><given-names>D.S.S.</given-names></name><name name-style="western"><surname>Mathias</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Yukuyama</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Scarim</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>L&#246;benberg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bou-Chacra</surname><given-names>N.A.</given-names></name></person-group><article-title>Promising Nanotherapy in Treating Leishmaniasis</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>547</volume><fpage>421</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.06.018</pub-id><pub-id pub-id-type="pmid">29886097</pub-id></element-citation></ref><ref id="B61-pharmaceutics-17-01216"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>de Ara&#250;jo</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Giarolla</surname><given-names>J.</given-names></name><name name-style="western"><surname>Seoud</surname><given-names>O.E.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>E.I.</given-names></name></person-group><article-title>Searching for Drugs for Chagas Disease, Leishmaniasis and Schistosomiasis: A Review</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><volume>55</volume><fpage>105906</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105906</pub-id><pub-id pub-id-type="pmid">31987883</pub-id></element-citation></ref><ref id="B62-pharmaceutics-17-01216"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alishahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khorram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Asgari</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Davani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Goudarzi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Emami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arastehfar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zomorodian</surname><given-names>K.</given-names></name></person-group><article-title>Glucantime-Loaded Electrospun Core-Shell Nanofibers Composed of Poly(Ethylene Oxide)/Gelatin-Poly(Vinyl Alcohol)/Chitosan as Dressing for Cutaneous Leishmaniasis</article-title><source>Int. J. Biol. Macromol.</source><year>2020</year><volume>163</volume><fpage>288</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.06.240</pub-id><pub-id pub-id-type="pmid">32610052</pub-id></element-citation></ref><ref id="B63-pharmaceutics-17-01216"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahmoud Abd-Alaziz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mansour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nasr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sammour</surname><given-names>O.</given-names></name></person-group><article-title>Tailored Green Synthesized Silymarin-Selenium Nanoparticles: Topical Nanocarrier of Promising Antileishmanial Activity</article-title><source>Int. J. Pharm.</source><year>2024</year><volume>660</volume><fpage>124275</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2024.124275</pub-id><pub-id pub-id-type="pmid">38797252</pub-id></element-citation></ref><ref id="B64-pharmaceutics-17-01216"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lanza</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Vucen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>O.</given-names></name><name name-style="western"><surname>Donadei</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cojean</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loiseau</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>A.P.S.M.</given-names></name><name name-style="western"><surname>Fr&#233;zard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>A.C.</given-names></name></person-group><article-title>A TLR9-Adjuvanted Vaccine Formulated into Dissolvable Microneedle Patches or Cationic Liposomes Protects against Leishmaniasis after Skin or Subcutaneous Immunization</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>586</volume><fpage>119390</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119390</pub-id><pub-id pub-id-type="pmid">32540349</pub-id></element-citation></ref><ref id="B65-pharmaceutics-17-01216"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maria Jose Alves De</surname><given-names>O.</given-names></name><name name-style="western"><surname>Regina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lucia Almeida</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ademar Benevolo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Valdir Sabbaga</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duclerc Fernandes</surname><given-names>P.</given-names></name></person-group><article-title>Topical Treatment of Cutaneous Leishmaniasis: Wound Reduction in Mice Using N-Methyl Glucamine from PVP and Nano Clay Membranes</article-title><source>J. Dermatol. Res. Ther.</source><year>2016</year><volume>2</volume><fpage>10</fpage><lpage>23937</lpage><pub-id pub-id-type="doi">10.23937/2469-5750/1510036</pub-id></element-citation></ref><ref id="B66-pharmaceutics-17-01216"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>M.J.A.D.</given-names></name><name name-style="western"><surname>Villegas</surname><given-names>G.M.E.</given-names></name><name name-style="western"><surname>Motta</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Fabela-S&#225;nchez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Espinosa-Roa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fotoran</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Peixoto</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Tano</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Lug&#227;o</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>V&#225;squez</surname><given-names>P.A.S.</given-names></name></person-group><article-title>Influence of Gamma Radiation on Amphotericin B Incorporated in PVP Hydrogel as an Alternative Treatment for Cutaneous Leishmaniosis</article-title><source>Acta Trop.</source><year>2021</year><volume>215</volume><fpage>105805</fpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2020.105805</pub-id><pub-id pub-id-type="pmid">33387468</pub-id></element-citation></ref><ref id="B67-pharmaceutics-17-01216"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puttappa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Kuppusamy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Radhakrishnan</surname><given-names>A.</given-names></name></person-group><article-title>Nano-Facilitated Drug Delivery Strategies in the Treatment of Plasmodium Infection</article-title><source>Acta Trop.</source><year>2019</year><volume>195</volume><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2019.04.020</pub-id><pub-id pub-id-type="pmid">31039335</pub-id></element-citation></ref><ref id="B68-pharmaceutics-17-01216"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Qamar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ashrafi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fatima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Samim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mohmmed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abdin</surname><given-names>M.Z.</given-names></name></person-group><article-title>Emerging Nanotechnology-Driven Drug Delivery Solutions for Malaria: Addressing Drug Resistance and Improving Therapeutic Success</article-title><source>Int. J. Pharm.</source><year>2025</year><volume>670</volume><fpage>125163</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2024.125163</pub-id><pub-id pub-id-type="pmid">39788401</pub-id></element-citation></ref><ref id="B69-pharmaceutics-17-01216"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baruah</surname><given-names>U.K.</given-names></name><name name-style="western"><surname>Gowthamarajan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ravisankar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Karri</surname><given-names>V.V.S.R.</given-names></name><name name-style="western"><surname>Simhadri</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>V.</given-names></name></person-group><article-title>Optimisation of Chloroquine Phosphate Loaded Nanostructured Lipid Carriers Using Box-Behnken Design and Its Antimalarial Efficacy</article-title><source>J. Drug Target.</source><year>2018</year><volume>26</volume><fpage>576</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1080/1061186X.2017.1390671</pub-id><pub-id pub-id-type="pmid">29057679</pub-id></element-citation></ref><ref id="B70-pharmaceutics-17-01216"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuntworbe</surname><given-names>N.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>J.</given-names></name><name name-style="western"><surname>Al-Kassas</surname><given-names>R.</given-names></name></person-group><article-title>Malaria Intervention Policies and Pharmaceutical Nanotechnology as a Potential Tool for Malaria Management</article-title><source>Drug Dev. Res.</source><year>2012</year><volume>73</volume><fpage>167</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1002/ddr.21010</pub-id></element-citation></ref><ref id="B71-pharmaceutics-17-01216"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos-Magalh&#227;es</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Mosqueira</surname><given-names>V.C.F.</given-names></name></person-group><article-title>Nanotechnology Applied to the Treatment of Malaria</article-title><source>Adv. Drug Deliv. Rev.</source><year>2010</year><volume>62</volume><fpage>560</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2009.11.024</pub-id><pub-id pub-id-type="pmid">19914313</pub-id></element-citation></ref><ref id="B72-pharmaceutics-17-01216"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eastman</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Fidock</surname><given-names>D.A.</given-names></name></person-group><article-title>Artemisinin-Based Combination Therapies: A Vital Tool in Efforts to Eliminate Malaria</article-title><source>Nat. Rev. Microbiol.</source><year>2009</year><volume>7</volume><fpage>864</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2239</pub-id><pub-id pub-id-type="pmid">19881520</pub-id><pub-id pub-id-type="pmcid">PMC2901398</pub-id></element-citation></ref><ref id="B73-pharmaceutics-17-01216"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenechukwu</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Ugwu</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Chukwu</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Anikwe</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Okaudu</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Momoh</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ricci-Junior</surname><given-names>E.</given-names></name><name name-style="western"><surname>Attama</surname><given-names>A.A.</given-names></name></person-group><article-title>Transdermal Films and Nanogels as Toolboxes for Novel Generation of Non-Invasive Antimalarial Pharmaceuticals in Dermatology: A Comprehensive Review</article-title><source>Biomed. Mater. Devices</source><year>2025</year><volume>3</volume><fpage>1</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1007/s44174-025-00372-8</pub-id></element-citation></ref><ref id="B74-pharmaceutics-17-01216"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zech</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dzikowski</surname><given-names>R.</given-names></name><name name-style="western"><surname>Simantov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Golenser</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maeder</surname><given-names>K.</given-names></name></person-group><article-title>Transdermal Delivery of Artemisinins for Treatment of Pre-Clinical Cerebral Malaria</article-title><source>Int. J. Parasitol.-Drugs Drug Resist.</source><year>2021</year><volume>16</volume><fpage>148</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.ijpddr.2021.05.008</pub-id><pub-id pub-id-type="pmid">34116478</pub-id><pub-id pub-id-type="pmcid">PMC8203570</pub-id></element-citation></ref><ref id="B75-pharmaceutics-17-01216"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dwivedi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mazumder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Br&#252;mmer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Du Preez</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Du Plessis</surname><given-names>J.</given-names></name></person-group><article-title>In Vitro Skin Permeation of Artemisone and Its Nano-Vesicular Formulations</article-title><source>Int. J. Pharm.</source><year>2016</year><volume>503</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.02.041</pub-id><pub-id pub-id-type="pmid">26930566</pub-id></element-citation></ref><ref id="B76-pharmaceutics-17-01216"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dandekar</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhumal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vanage</surname><given-names>G.</given-names></name><name name-style="western"><surname>Patravale</surname><given-names>V.</given-names></name></person-group><article-title>Curcumin-Loaded Hydrogel Nanoparticles: Application in Anti-Malarial Therapy and Toxicological Evaluation</article-title><source>J. Pharm. Sci.</source><year>2010</year><volume>99</volume><fpage>4992</fpage><lpage>5010</lpage><pub-id pub-id-type="doi">10.1002/jps.22191</pub-id><pub-id pub-id-type="pmid">20821383</pub-id></element-citation></ref><ref id="B77-pharmaceutics-17-01216"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alfrd Mavondo</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Tagumirwa</surname><given-names>M.C.</given-names></name></person-group><article-title>Asiatic Acid-Pectin Hydrogel Matrix Patch Transdermal Delivery System Influences Parasitaemia Suppression and Inflammation Reduction in P. Berghei Murine Malaria Infected Sprague&#8212;Dawley Rats</article-title><source>Asian Pac. J. Trop. Med.</source><year>2016</year><volume>9</volume><fpage>1172</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1016/j.apjtm.2016.10.008</pub-id><pub-id pub-id-type="pmid">27955745</pub-id></element-citation></ref><ref id="B78-pharmaceutics-17-01216"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nnamani</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Windbergs</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lehr</surname><given-names>C.-M.</given-names></name></person-group><article-title>Development of Artemether-Loaded Nanostructured Lipid Carrier (NLC) Formulation for Topical Application</article-title><source>Int. J. Pharm.</source><year>2014</year><volume>477</volume><fpage>208</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.10.004</pub-id><pub-id pub-id-type="pmid">25290810</pub-id></element-citation></ref><ref id="B79-pharmaceutics-17-01216"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ananda</surname><given-names>P.W.R.</given-names></name><name name-style="western"><surname>Elim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zaman</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Muslimin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tunggeng</surname><given-names>M.G.R.</given-names></name><name name-style="western"><surname>Permana</surname><given-names>A.D.</given-names></name></person-group><article-title>Combination of Transdermal Patches and Solid Microneedles for Improved Transdermal Delivery of Primaquine</article-title><source>Int. J. Pharm.</source><year>2021</year><volume>609</volume><fpage>121204</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.121204</pub-id><pub-id pub-id-type="pmid">34662646</pub-id></element-citation></ref><ref id="B80-pharmaceutics-17-01216"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Medeiros</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Alves Pereira</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Da Silva</surname><given-names>J.F.O.</given-names></name><name name-style="western"><surname>De Freitas Oliveira</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Fernandes-Pedrosa</surname><given-names>M.D.F.</given-names></name><name name-style="western"><surname>De Sousa Da Silva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Da Silva-J&#250;nior</surname><given-names>A.A.</given-names></name></person-group><article-title>From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>13778</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241813778</pub-id><pub-id pub-id-type="pmid">37762080</pub-id><pub-id pub-id-type="pmcid">PMC10530915</pub-id></element-citation></ref><ref id="B81-pharmaceutics-17-01216"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Permana</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Paredes</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Zanutto</surname><given-names>F.V.</given-names></name><name name-style="western"><surname>Amir</surname><given-names>M.u.h.N.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bahar</surname><given-names>M.u.h.A.</given-names></name><name name-style="western"><surname>Sumarheni Palma</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name></person-group><article-title>Albendazole Nanocrystal-Based Dissolving Microneedles with Improved Pharmacokinetic Performance for Enhanced Treatment of Cystic Echinococcosis</article-title><source>ACS Appl. Mater. Interfaces</source><year>2021</year><volume>13</volume><fpage>38745</fpage><lpage>38760</lpage><pub-id pub-id-type="doi">10.1021/acsami.1c11179</pub-id><pub-id pub-id-type="pmid">34353029</pub-id></element-citation></ref><ref id="B82-pharmaceutics-17-01216"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devineni</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pravallika</surname><given-names>C.h.D.</given-names></name><name name-style="western"><surname>Sudha Rani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nalluri</surname><given-names>B.N.</given-names></name></person-group><article-title>Effective Single Drug Treatment of Lymphatic Filariasis through Enhanced Transdermal Delivery of Ivermectin Liposomes Using Solid and Dissolving Microneedles</article-title><source>Indian J. Pharm. Educ. Res.</source><year>2020</year><volume>54</volume><fpage>s492</fpage><lpage>s504</lpage><pub-id pub-id-type="doi">10.5530/ijper.54.3s.148</pub-id></element-citation></ref><ref id="B83-pharmaceutics-17-01216"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Permana</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Tekko</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>McCrudden</surname><given-names>M.T.C.</given-names></name><name name-style="western"><surname>Anjani</surname><given-names>Q.K.</given-names></name><name name-style="western"><surname>Ramadon</surname><given-names>D.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name></person-group><article-title>Solid Lipid Nanoparticle-Based Dissolving Microneedles: A Promising Intradermal Lymph Targeting Drug Delivery System with Potential for Enhanced Treatment of Lymphatic Filariasis</article-title><source>J. Control. Release</source><year>2019</year><volume>316</volume><fpage>34</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.10.004</pub-id><pub-id pub-id-type="pmid">31655132</pub-id></element-citation></ref><ref id="B84-pharmaceutics-17-01216"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manna</surname><given-names>O.</given-names></name><name name-style="western"><surname>Nditanchou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Siewe Fodjo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Colebunders</surname><given-names>R.</given-names></name></person-group><article-title>Utilization of Health Facilities and Schools in Onchocerciasis Elimination Efforts</article-title><source>IJID Reg.</source><year>2025</year><volume>16</volume><fpage>100677</fpage><pub-id pub-id-type="doi">10.1016/j.ijregi.2025.100677</pub-id><pub-id pub-id-type="pmid">40606591</pub-id><pub-id pub-id-type="pmcid">PMC12209935</pub-id></element-citation></ref><ref id="B85-pharmaceutics-17-01216"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okumura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Torii</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>K.</given-names></name><name name-style="western"><surname>Iwade</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name></person-group><article-title>A Case Report of Disseminated Strongyloidiasis Following Chemoradiotherapy for Lung Cancer in a Patient Living in a Non-Endemic Area in Japan</article-title><source>Intern. Med.</source><year>2025</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.5829-25</pub-id><pub-id pub-id-type="pmid">40707225</pub-id></element-citation></ref><ref id="B86-pharmaceutics-17-01216"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Chia</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Macbeath</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shlieout</surname><given-names>G.</given-names></name></person-group><article-title>Development of Microemulsion Based Topical Ivermectin Formulations: Pre-Formulation and Formulation Studies</article-title><source>Colloids Surf. B Biointerfaces</source><year>2020</year><volume>189</volume><elocation-id>110823</elocation-id><pub-id pub-id-type="doi">10.1016/j.colsurfb.2020.110823</pub-id><pub-id pub-id-type="pmid">32036331</pub-id></element-citation></ref><ref id="B87-pharmaceutics-17-01216"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awad</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rawas-Qalaji</surname><given-names>M.</given-names></name><name name-style="western"><surname>El Hosary</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jagal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>I.S.</given-names></name></person-group><article-title>Formulation and Optimization of Ivermectin Nanocrystals for Enhanced Topical Delivery</article-title><source>Int. J. Pharm. X</source><year>2023</year><volume>6</volume><fpage>100210</fpage><pub-id pub-id-type="doi">10.1016/j.ijpx.2023.100210</pub-id><pub-id pub-id-type="pmid">37727680</pub-id><pub-id pub-id-type="pmcid">PMC10506092</pub-id></element-citation></ref><ref id="B88-pharmaceutics-17-01216"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steenekamp</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Liebenberg</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lemmer</surname><given-names>H.J.R.</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>M.</given-names></name></person-group><article-title>Formulation and Ex Vivo Evaluation of Ivermectin Within Different Nano-Drug Delivery Vehicles for Transdermal Drug Delivery</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>1466</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16111466</pub-id><pub-id pub-id-type="pmid">39598589</pub-id><pub-id pub-id-type="pmcid">PMC11597838</pub-id></element-citation></ref><ref id="B89-pharmaceutics-17-01216"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velho</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Funk</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Deon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benvenutti</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Buchner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hinrichs</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pilger</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>R.C.R.</given-names></name></person-group><article-title>Ivermectin-Loaded Mesoporous Silica and Polymeric Nanocapsules: Impact on Drug Loading, In Vitro Solubility Enhancement, and Release Performance</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>325</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16030325</pub-id><pub-id pub-id-type="pmid">38543218</pub-id><pub-id pub-id-type="pmcid">PMC10974340</pub-id></element-citation></ref><ref id="B90-pharmaceutics-17-01216"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Penetration Enhancer-Free Mixed Micelles for Improving Eprinomectin Transdermal c Efficiency in Animal Parasitic Infections Therapy</article-title><source>Int. J. Nanomed.</source><year>2024</year><volume>19</volume><fpage>11071</fpage><lpage>11085</lpage><pub-id pub-id-type="doi">10.2147/IJN.S476164</pub-id><pub-id pub-id-type="pmcid">PMC11537163</pub-id><pub-id pub-id-type="pmid">39502637</pub-id></element-citation></ref><ref id="B91-pharmaceutics-17-01216"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Rustum</surname><given-names>A.M.</given-names></name></person-group><article-title>A Comprehensive Study to Identify Major Degradation Products of Avermectin Active Ingredient Using High Resolution LCMS and NMR</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>2025</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1080/10826076.2025.2493203</pub-id></element-citation></ref><ref id="B92-pharmaceutics-17-01216"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Souza</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Bockarie</surname><given-names>M.J.</given-names></name></person-group><article-title>Current Perspectives in the Epidemiology and Control of Lymphatic Filariasis</article-title><source>Clin. Microbiol. Rev.</source><year>2025</year><volume>38</volume><elocation-id>e00126-23</elocation-id><pub-id pub-id-type="doi">10.1128/cmr.00126-23</pub-id><pub-id pub-id-type="pmid">40172233</pub-id><pub-id pub-id-type="pmcid">PMC12160566</pub-id></element-citation></ref><ref id="B93-pharmaceutics-17-01216"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karakoyun</surname><given-names>&#214;.</given-names></name><name name-style="western"><surname>Ayhan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Y&#305;ld&#305;z</surname><given-names>&#304;.</given-names></name></person-group><article-title>Effect of Ivermectin on Scabies: A Retrospective Evaluation</article-title><source>BMC Infect. Dis.</source><year>2025</year><volume>25</volume><elocation-id>937</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-025-11315-5</pub-id><pub-id pub-id-type="pmid">40702460</pub-id><pub-id pub-id-type="pmcid">PMC12288330</pub-id></element-citation></ref><ref id="B94-pharmaceutics-17-01216"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karpstein</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kalamatianou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Spane</surname><given-names>P.</given-names></name><name name-style="western"><surname>Haberli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Odermatt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blacque</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cariou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gasser</surname><given-names>G.</given-names></name><name name-style="western"><surname>Keiser</surname><given-names>J.</given-names></name></person-group><article-title>Synthesis and Multidisciplinary Preclinical Investigations of Ferrocenyl, Ruthenocenyl, and Benzyl Derivatives of Thiabendazole as New Drug Candidates against Soil-Transmitted Helminth Infections</article-title><source>ACS Infect. Dis.</source><year>2025</year><volume>11</volume><fpage>2037</fpage><lpage>2047</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.5c00340</pub-id><pub-id pub-id-type="pmid">40524143</pub-id></element-citation></ref><ref id="B95-pharmaceutics-17-01216"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Research Progress on Benzimidazole Fungicides: A Review</article-title><source>Molecules</source><year>2024</year><volume>29</volume><elocation-id>1218</elocation-id><pub-id pub-id-type="doi">10.3390/molecules29061218</pub-id><pub-id pub-id-type="pmid">38542855</pub-id><pub-id pub-id-type="pmcid">PMC10975326</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-01216-f001" orientation="portrait"><label>Figure 1</label><caption><p>Zoonotic Parasitic Diseases under the One Health Framework (Take Toxoplasma gondii as an example). This figure illustrates the One Health concept via Toxoplasma gondii and arthropod-borne diseases. Blue: Foodborne T. gondii infects humans (e.g., pregnant women) via contaminated meat/produce, potentially causing neurological damage or miscarriage. Green: Cats (definitive hosts) shed oocysts, which contaminate water and soil via rain. Intermediate hosts (e.g., pigs) ingest oocysts; humans risk infection through environmental contact or undercooked meat. Purple: Arthropods (ticks, mosquitoes) cause rashes, fever, itching, and transmit diseases (Lyme, dengue) and pathogens (babesiosis, endemic typhus), embodying the interconnection of human, animal, and environmental health&#8212;the core of One Health.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01216-g001.jpg"/></fig><fig position="float" id="pharmaceutics-17-01216-f002" orientation="portrait"><label>Figure 2</label><caption><p>Pathways of transdermal absorption of nanoformulated drugs. This figure illustrates transdermal delivery modalities of nanoformulations. Polymeric nanocarriers, nanoemulsions, liposomes, niosomes, solid lipid nanoparticles (SLNs), and microneedles enable penetration across the skin strata (epidermis and dermis). Leveraging follicular and transcellular/paracellular pathways, these systems exemplify advanced nanocarrier-mediated strategies for percutaneous therapeutic administration.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01216-g002.jpg"/></fig><fig position="float" id="pharmaceutics-17-01216-f003" orientation="portrait"><label>Figure 3</label><caption><p>Examples for transdermal nanoformulations against leishmaniasis and malaria. This figure illustrates nanotherapeutic mechanisms against Leishmaniasis (left) and Malaria (right). Silymarin-selenium nanoparticles enhance drug loading, promote cellular uptake, and inhibit trithiol reductase for Leishmaniasis. Artemisininone solid lipid nanoparticles boost epidermal drug concentration in the stratum corneum to treat Malaria, showcasing nano-based strategies for parasitic diseases.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01216-g003.jpg"/></fig><fig position="float" id="pharmaceutics-17-01216-f004" orientation="portrait"><label>Figure 4</label><caption><p>Mechanism of ivermectin nanoemulsion in treating strongyloidiasis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01216-g004.jpg"/></fig><fig position="float" id="pharmaceutics-17-01216-f005" orientation="portrait"><label>Figure 5</label><caption><p>Mechanism of solid and lipid nanoparticle-dissolving microneedle system of albendazole. This figure illustrates the mechanism of solid lipid nanoparticle (SLN)&#8212;based dissolving microneedles for lymphatic <italic toggle="yes">filariasis</italic> treatment. ABZ-OX-loaded SLNs penetrate the skin via microneedles and target lymphatic vessels. Advantages include high drug-targeting efficiency and direct transport rate, disrupting microtubules and inhibiting the energy metabolism of filarial parasites for effective therapy.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01216-g005.jpg"/></fig><table-wrap position="float" id="pharmaceutics-17-01216-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01216-t001_Table 1</object-id><label>Table 1</label><caption><p>Nanoformulations of antiparasitic drugs for zoonotic diseases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nanoformulation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compounds</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Advantages</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Type and Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formulation Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="10" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Leishmaniasis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transfersomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trifluralin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High transdermal efficiency, high encapsulation efficiency, sustained release, reduced IC<sub>50</sub> for Leishmania pathogens, high inhibition rate of amastigotes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo (Albino Wistar rats)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 140.3 &#177; 2.3 nm;<break/>PDI: 0.006 &#177; 0.002;<break/>%EE: 86 &#177; 0.5% and 43.5 &#177; 1.0%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-pharmaceutics-17-01216" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transfersomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nitazoxanide-quercetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced skin permeation, increased macrophage uptake, higher CC50, smaller lesion size, low systemic toxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro (PMs) In vivo (Male Albino Wistar rats, BALB/c mice)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 210 nm;<break/>PDI: 0.16;<break/>ZP: &#8722;15.1 mV;<break/>EE of NTZ and QUR was 88% and 85%.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-pharmaceutics-17-01216" ref-type="bibr">21</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoemulsions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3&#8242;-(Trifluoromethyl)-chalcone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High dermal permeation amount, high skin retention</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro (TH-1) in vivo (Pigs)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 179.0 &#177; 1.0 nm;<break/>PDI: &lt;0.3;<break/>%EE: ~100%;<break/>|ZP|: &gt; 30 mV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-pharmaceutics-17-01216" ref-type="bibr">25</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoemulsions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C6I/TC1/TC2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced skin permeation, Sustained release, high parasiticidal activity, low macrophage cytotoxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro (U-937-CRL-1593.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-pharmaceutics-17-01216" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electrospun core&#8211;shell nanofibers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glucantime</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stable drug release, maintenance of effective drug concentration for a long time, sustained therapeutic effect</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro (NIH3T3, Franz diffusion cell)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-pharmaceutics-17-01216" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silymarin-selenium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High drug loading capacity, high skin deposition rate, significant reduction in local treatment toxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro (NHDFa) In vivo (Male Wistar rats)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%LE: 58.22 &#177; 0.56%;<break/>HD: 245.77 &#177; 11.12 nm;<break/>PDI: 0.19 &#177; 0.01;<break/>ZP: &#8722;30.63 &#177; 0.40 mV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B63-pharmaceutics-17-01216" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transfersomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifampicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High skin permeability, targeted reduction of IC<sub>50</sub> value</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro (Macrophages) and in vivo (Albino Wistar rats, female BALB/c mice)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 190 nm,<break/>%EE: 83%;<break/>3-fold permeation vs. free RIF.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-pharmaceutics-17-01216" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanostructured lipid carrier</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glucantime</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controlled drug release, enhanced skin retention, reduced systemic toxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro (L. major) and in vivo (female BALB/c mice)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 93.87&#8201;&#177;&#8201;0.1&#8201;nm;<break/>PDI: 0.295&#8201;&#177;&#8201;0.015;<break/>ZP: &#8722;30.31&#8201;&#177;&#8201;0.25&#8201;mV;<break/>%LE: 74&#8201;&#177;&#8201;0.37%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-pharmaceutics-17-01216" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanofibers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Berberine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gradient release, excellent biocompatibility, stable release rate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro (J774A.1, L. major) and in vivo (female BALB/c mice)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 10.51 &#177; 0.24 nm;<break/>PDI: 0.19 &#177; 0.03;<break/>ZP: &#8722;0.41 &#177; 0.17 mV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023, 2024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmaceutics-17-01216" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-01216" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microneedle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aphotericin B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved skin permeability, minimal cellular damage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro (HT-29,) In vivo (Sprague-Dawley male rats)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug Loading: 182 &#177; 4 &#956;g per (22 &#215; 22) MN array</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-pharmaceutics-17-01216" ref-type="bibr">31</xref>]</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">Malaria</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ethosomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artesunate and Febrifugine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High cumulative permeation, high efficiency</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo (Specific-pathogen-free male Kunming mice)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 26.48 &#177; 0.12 nm;<break/>ZP: &#8722;28.0 &#177; 1.6 mV;<break/>PDI: 0.195 &#177; 0.005;<break/>%EE: 71.81 &#177; 2.57%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B22-pharmaceutics-17-01216" ref-type="bibr">22</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid lipid nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artemisone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High skin delivery concentration</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro (Caucasian female skin obtained by abdominoplasty)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 295 &#177; 18 nm;<break/>ZP: &#8722;12 &#177; 3 mV;<break/>%EE: 79 &#177; 5.00%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-pharmaceutics-17-01216" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elastic liposomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PfMSP-119</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Efficient targeting, long-lasting immune response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-pharmaceutics-17-01216" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curcumin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High antimalarial activity, prolonged drug circulation time, high bioavailability, enhanced therapeutic efficacy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Albino nude rat, Balb/c mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015, 2016, 2010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-pharmaceutics-17-01216" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-17-01216" ref-type="bibr">48</xref>,<xref rid="B76-pharmaceutics-17-01216" ref-type="bibr">76</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanostructured lipid carrier</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artemether</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High cumulative permeation rate, high drug stability, high release controllability</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro (Caucasian female skin obtained by abdominoplasty)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B78-pharmaceutics-17-01216" ref-type="bibr">78</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microneedles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primaquine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Optimal performance, safe for long-term medication</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro and in vivo<break/>(Wistar rats)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro and ex vivo permeation/release: 31.31 &#177; 5.25% and 22.55 &#177; 4.35%.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B79-pharmaceutics-17-01216" ref-type="bibr">79</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cystic Echinococcosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microneedle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Albendazole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High transdermal permeation amount, safe</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro and in vivo (rats)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmaceutics-17-01216" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microneedles-Nanocrystals system</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Albendazole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High transdermal depth, high peak drug concentration, long half-life</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wistar rats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B81-pharmaceutics-17-01216" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Lymphatic filariasis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid lipid nanoparticle&#8212;microneedle system</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Albendazole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High drug targeting efficiency, high direct transport rate, Sustained release, reduced metabolite generation, low drug distribution in liver and kidney</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro and in vivo (female Sprague&#8211;Dawley rats)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 95.25 &#177; 9.26 nm;<break/>PDI: 0.273 &#177; 0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-pharmaceutics-17-01216" ref-type="bibr">83</xref>]</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Scabies</italic>,<break/><italic toggle="yes">Rosacea</italic>,<break/><italic toggle="yes">Head lice</italic>,<break/><italic toggle="yes">Trichuriasis</italic>, <italic toggle="yes">Onchocerciasis</italic>,<break/><italic toggle="yes">Lymphatic filariasis</italic>, <italic toggle="yes">Strongyloidiasis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microemulsion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ivermectin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved membrane permeability, high solubility</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 18&#8211;54 nm;<break/>PDI: 0.3&#8211;0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-pharmaceutics-17-01216" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanocrystals</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ivermectin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High equilibrium solubility, fast dissolution rate, high dermal deposition, low side effects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro<break/>(Adult pig ear skin)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 186 nm;<break/>PDI: 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B87-pharmaceutics-17-01216" ref-type="bibr">87</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoemulsion (NE)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ivermectin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Highest drug concentration in stratum corneum and epidermis/dermis junction</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">In vitro<break/>(HaCaT, BJ-5ta, female skin obtained by abdominoplasty)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 57.157 &#177; 0.455nm;<break/>PDI: 0.165 &#177; 0.014;<break/>ZP: &#8722;30.600 &#177; 1.300 mV</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2024</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B88-pharmaceutics-17-01216" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoemulsion gel (NEG)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ivermectin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fastest delivery rate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 106.900 &#177; 0.490nm;<break/>PDI: 0.287 &#177; 0.037;<break/>ZP: &#8722;40.400 &#177; 1.283 mV</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colloidal system (CS)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ivermectin </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Highest drug diffusion percentage, efficient delivery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ZP: &#8722;36.200 &#177; 0.666 mV</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid lipid nanoparticles </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ivermectin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sustained-release efficacy, targeting, low systemic toxicity, few side effects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%EE: 99.9&#177;0.0%;<break/>%LC: 5.0 &#177; 0.0%,</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-pharmaceutics-17-01216" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ivermectin </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">suitable for acute infection management</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DL: 10.7%;<break/>&gt;90% drug recovery</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2024</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B89-pharmaceutics-17-01216" ref-type="bibr">89</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanocapsules</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ivermectin </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">suitable for chronic prevention</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Z-average: 202 &#177; 2 nm;<break/>ZP: &#8722;17 &#177; 0.5 mV;<break/>PDI: 0.12 &#177; 0.01</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hybrid micelles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eprinomectin </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High permeability, low toxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro &amp; In vivo (Male Sprague&#8211;Dawley rats, Male ICR mice)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PS: 13.97 &#177; 0.16 nm;<break/>PDI: 0.132;<break/>%LE: 0.49%;<break/>%EE: 95.81%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-pharmaceutics-17-01216" ref-type="bibr">90</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Note: &#8220;/&#8221; indicates that no information was found or is not available. PS: particle size; PDI: polydispersity index; DL: drug loading; EE:entrapped efficiency; HD: Hydrate; ZP: zeta potential.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>